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Breast cancer is the most common malignancy in women with more, than 8.400 newly 
diagnosed cases and nearly 2.200 deaths in 2017, according to the Hungarian National Cancer 
Registry [1]. Breast cancer treatment has gone through a long evolutional process from 
Halsted’s procedure to nowadays’ complex multidisciplinary approach and oncoplastic surgical 
procedures on the last decades [2-4]. The introduction of populational based breast screening 
programmes, supported by the development of molecular biology, histology, radio-, and 
oncotherapy resulted in a significant increase in five-year survival rate (from 52% to 85.1%) 
[5-7]. 
With the scientific endorsement of oncoplastic breast surgery, the main focus of breast 
cancer treatment shifted to higher level issues targeting treatment optimization by the de-
escalation or escalation of the current protocols [8]: active surveillance or surgery for low-risk 
DCIS, the role and indication of nipple-sparing mastectomy (NSM), questions of the surgical 
margins, sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT), 
omitting axillary lymph node dissection (ALND) or targeted axillary surgery [9-13]. 
The hypotheses of this dissertation also aimed to evaluate advanced level issues of 
modern breast surgery: the correlations of the lymphatic drainage pattern of the breast which 
may provide further basic information for the interpretation of American College of Surgeons 
Oncology Group (ACOSOG) Z0011, Optimal Treatment Of the Axilla – Surgery or 
Radiotherapy (OTOASOR) and After Mapping of the Axilla: Radiotherapy Or Surgery 
(AMAROS) trials; the cosmetic role and oncologic importance of the nipple-areola complex 
(NAC) and its components in the context of the preservation of the complex anatomical unit of 
the nipple by NSMs or only the pigmented kin of the areola by areola-sparing mastectomies 
(ASM) and today’s yet invisible questions, the needs and requirements of the Hungarian health 
care system due to the rapid expansion of oncoplastic breast surgery. 
1.1. Anatomy of the subregions of the axilla and its importance in breast cancer treatment 
Anatomically, the axillary region is divided into five subregions: anterior, posterior, 
lateral, central and apical zones [14] (Figure 1.). 
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The anterior subregion is located under the lateral edge of the pectoralis minor muscle 
along the lateral thoracic vein. The posterior zone is found adjacent to the posterior wall of the 
axilla along the thoracodorsal nerve and vessels. The lateral subregion is located close to the 
lateral wall of the axilla, in relation to the proximal part of the axillary vein. The lymph nodes 
in this zone receive the vast majority of the efferent lymph vessels of the upper limb. The central 
zone is in the middle of the pyramid-shaped space of the armpit, close to the base of the axilla. 
The apical subregion is found in the apex medially to the distal part of the axillary vein. 
These subregions correspond to the axillary node levels previously described by Berg 
[15]. The anterior, posterior and lateral subregions constitute Level I, the central zone forms 
Level II and the apical zone constitutes Level III [14].  
Clear relationships between the anatomic location and metastatic status of the sentinel 
lymph node (SLN) have been revealed [16, 17]. Histologically positive SLN was detected in 
Level I in 96% of cases and in Level II in 4% of cases by SPECT/CT [17]. 
 
 
Figure 1. Subregions of the axilla (left side, human cadaveric dissection) 
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Regional lymph node status is one of the most important prognostic factors for disease-
free (DFS) and overall survival (OS) in breast cancer [18-22]. Today, the gold-standard method 
for staging patients with early-stage breast cancer with clinically negative axillary lymph nodes 
is the SLNB [21, 22]. 
To optimise the effectiveness of SLNB, the precise pre- and intraoperative mapping of 
lymphatic drainage is mandatory[21-23]. 
A better understanding of the relationships between the subregional drainage pattern of 
SLN, the subregional localisation of SLN and the correlation to location and pathological 
characteristics of the primary breast tumour could have particular importance in determining 
whether ALND can be safely omitted. 
The ACOSOG Z0011 trial did not perform ALND for early-stage breast cancer patients 
with 1-2 metastatic SLNs (cT1-2, pN1), and in the majority of the patients, the axilla was treated 
only with tangential field irradiation following breast-conserving surgery (BCS). After a 
median follow-up of 9.3 years, the data compared to the traditional ALND group showed no 
differences in local recurrence-free survival [24, 25]. However, in the ACOSOG Z0011 trial, 
dose distribution in the axillary volumes was not reported in the initial publication. Jagsi et al. 
[26] recently analysed the radiotherapy (RT) coverage of the axillary lymph nodes of that trial. 
Most patients treated in the Z0011 trial received tangential RT alone, and some received no RT 
at all. Some patients received directed nodal irradiation via a third field. They concluded that 
further research is necessary to determine the optimal RT approach in patients with low-volume 
axillary disease treated with SLNB alone. 
A recent surgical technique that is less radical and therefore decreases the morbidity of 
SLNB and ALND, especially lymphedema, is axillary reverse mapping (ARM) [27-29]. The 
lymphatic drainage of the upper limb that runs through the axilla - most often the lateral 
subregional lymphatic structures - is identified by injecting radioisotope or blue dye to the 
ipsilateral limb subcutaneously, and these nodes are spared during the operation, removing only 
the lymph nodes that drain the lymph of the breast. The technique was proven to be feasible 
with a low level of evidence; however, the question of oncological radicality still arises due to 
the uncertainty of the metastatic status of the ARM lymph nodes that are not removed [30]. 
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1.2. Anatomy of the nipple-areola complex and its importance in breast cancer treatment 
In recent decades, several types of mastectomy have been developed to enhance the 
cosmetic outcomes of immediate breast reconstructions and therefore patient satisfaction; these 
techniques include skin-sparing mastectomy (SSM), ASM and NSM. As a consequence, 
concerns of oncological safety have arisen in regard to not compromising cancer treatment by 
preserving the skin, especially the nipple [31, 32]. 
The main question behind the possible uncertainty of NSM is the anatomy of the NAC 
and the chance of cancer development in the remnant tissue after mastectomy. The nipple 
contains the ducts draining the mammary gland, but terminal ductal lobular units (TDLUs) - 
from where ductal and lobular breast cancer arise – can also be found in the NAC [33-37]. A 
recent anatomical study by Rusby et al. showed that the ducts form a central bundle in the nipple 
that narrows just under the skin before spreading to the breast parenchyma [38]. The central 
bundle is covered by a duct-free rim of tissue containing 50% of the vasculature of the nipple, 
allowing a complete ductal resection leaving a 2-mm peripheral rim behind without damaging 
the blood supply in 96% of the cases [39]. TDLUs can be present behind the areola in up to 25-
26% of cases [34, 36], but are located at the base of the nipple [37]. By understanding these 
sophisticated anatomical details, the duct core and the possible TDLUs can be excised by 
applying a careful dissection at the level of the dermis below the NAC, resulting in an 
oncologically safe and cosmetically superior nipple-sparing procedure [36, 40-42]. 
Up until the dispelling of oncological concerns regarding the preservation of the nipple, 
SSM was the preferred procedure for delayed-immediate breast reconstruction for suitable 
patients. Since the acceptance of NSM at the 13th St. Gallen International Breast Cancer 
Conference [43] and strengthening of its role and the broadening of its indications in the 
surgical treatment of breast cancer at the Oncoplastic Breast Consortium consensus conference 
on NSM in Basel [13], the importance of ASM has largely been reduced. 
However, if the nipple has to be removed for oncological reasons, the complexity of the 
anatomical and aesthetical substructure of the NAC comes into the highlight. In such indications 
the oncological and cosmetic importance (as well patient reported outcomes) of the nipple and 
separately the pigmented skin of the areola should have better known by the modern breast 
oncoplastic surgery.    
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1.3. The Hungarian system of oncoplastic breast cancer care and its requirements  
Due to inequalities in special needs oncology care, the first European Breast Cancer 
Conference (EBCC) in Florence in 1998 called for multidisciplinary breast therapy units, the 
conditional and quality assurance requirements for so-called "breast units" (BU) have been 
defined [44]. A working group of the European Organization for the Research and Treatment 
of Cancer (EORTC) and the European Society of Mastology (EUSOMA) has developed basic 
requirements for breast cancer specialists, which made the quality assurance control of 
specialist care possible [45]. The European Union of Medical Specialists (UEMS) and the 
European Society of Surgical Oncology (ESSO) established a breast surgery licensing exam in 
2010, in which the National Institute of Oncology (NIO) has been actively involved for years. 
At the second EBCC, the "Brussels Statement" established a set of accreditation criteria [46]. 
In 2019, ESSO, UEMS, the European Breast Cancer Coalition (Europa Donna), the European 
School of Oncology (ESO), the European Breast Cancer Research Association of Surgical 
Trialists (EUBREAST), the European Commission Initiative on Breast Cancer (ECIBC), the 
Hungarian-initiated Central-Eastern European Breast Cancer Surgical Consortium 
(CEEBCSC) and the Group for Reconstructive and Therapeutic Advancements (G.Re.T.A.) 
launched the Breast Surgical Oncology (BRESO) project [47]. The BRESO project has 
developed a continent-wide standardized breast surgery curriculum and quality assurance 
system and its accreditation requirements. As a result of these statements, the European 
Parliament issued a resolution in 2003 clearly supporting the extension of the institutional 
system of qualified BUs in Europe, and in 2013 a summary of the minimum requirements for 
Breast Centres was published [48]. 
The requirement for accredited BU certification is that in the given centre at least 150 
newly diagnosed breast cancer patients receive complex oncological treatment per year based 
on decisions of the multidisciplinary breast therapy committee, according to continuously 
updated professional protocols. An essential part of accreditation is the development and 
maintenance of a standardized database, the provision of population mammography screening 
programmes and the provision of educational and other scientific research activities [48-50]. 
The domestic situation and results of the BU system in Hungary was reported by our working 
group in the Orvosi Hetilap in 2016 [51].  
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As a consequence of the rapid spread of modern oncoplastic breast surgery in the recent 
decades, not only the removal of the breast tumour, but also the aesthetically complete 
preservation or post-mastectomy reconstruction of breasts is now an essential part of the 
surgical care [52-54]. In the absence of contraindications, any woman with breast cancer 
undergoing mastectomy should be offered and provided with the possibility of breast 
reconstruction [55]. The resulting demand for breast reconstruction not only poses a challenge 
for breast and plastic surgeons, but also raises a number of systemic issues in all European 
countries. 
Beside the basic reconstructive surgical procedures, however, additional indications and 
breast surgeries arising from the oncoplastic activity are awaiting clarification and regulation. 
The evaluation and controlled implementation of these extra procedures also contain a number 
of unknown factors even for the currently developed breast surgical care systems. 
The primary system-level breast reconstruction on wide population significantly 
expands the secondary tasks. As a result, new issues arise, which mean further load for the 
health care  system: aesthetic changes of the reconstructed or contralateral symmetrized breast 
due to weight gain known to occur as a result of long term (5-10 year long) endocrine treatment 
[56-58], “aging” secondary to the excellent survival [59-61] or fibrosis after the oncological 
treatments (e.g. RT) [62]. 
Beyond the above mentioned expectations, to determine the optimal volume of human 
resources and surgical capacity of the health care system, complications due to technical 
problems (e.g. implant rupture) or conditions (e.g. capsular contracture) of implants and the 
issue of the mass occurrence of further possible surgical corrections resulting from changes in 
contralateral breast symmetry should also be taken into account.   
Taking into consideration all the professional aspects, targeted aesthetic goal and the 
optimal and maximum number of reconstructive surgeries that can be performed within the 
framework of the oncology care system has to be determined. Oncoplastic care, as standard 
breast cancer surgical care, includes subjective indications or possible corrections for life-long 
cosmetic changes that go beyond primary oncology and reconstructive surgery and are often 
difficult to determine professionally. 
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Understanding, scientifically based identification and realistic assessment of new breast 
surgery needs is an essential basis for evolving the necessary set of conditions. At present, the 
National Health Insurance Fund of Hungary (Nemzeti Egészségbiztosítási Alapkezelő, NEAK) 
finances the reconstruction of the removed breast for all Hungarian insured persons, however, 
these complex new indications are currently not recognized at the system-level and are not 
managed accordingly. Breast reconstruction is a significant achievement for Hungarian breast 
cancer patients, but with the increase in the need for reconstruction and an expansion of the 
range of indications, an avalanche-like, unregulated situation may develop, the prevention of 
which requires professional knowledge and planning.  
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2. AIMS OF THE THESIS 
 
1. Assess relationship between the clinicopathological characteristic, the molecular genetical 
subtype and location by quadrants of the breast cancer and the subregions of the axilla and thus 
describe a functional and morphologic lymphatic drainage pattern 
 2. Assess the coverage of the axillary volumes by standard and high tangential fields (STgF 
and HTgF) for whole breast irradiation (WBI)  
3. Assess the SLN positivity rate in the lateral, undissected subregion when the ARM technique 
is applied 
4. Analyse the oncological and cosmetic importance of the NAC versus its components, the 
nipple and the pigmented skin of the areola 
5. Assess the opinions and needs of the Hungarian breast cancer population about a modern 






3. PATIENTS AND METHODS 
3.1. The retrospective cohort study of the mapping of the functional anatomy of lymphatic 
drainage to the axilla in early breast cancer. 
This study - registered on Clinicaltrials.gov (identifier: NCT01804309) and approved 
by the institutional ethical committee board - was performed between March 2013 and February 
2015 at the NIO, Hungary. 933 female patients older than 18 years were enrolled with primary 
unilateral invasive or microinvasive, clinically lymph node-negative early-stage breast cancer 
(clinically T≤5 cm, N0M0). Exclusion criteria included previous ALND, cN1-2, pregnancy, 
lactation and necessity of neoadjuvant treatment for breast cancer [63, 64]. 
SLNB technique 
The complex oncological therapy was performed according to the actual international 
guidelines [63-65] adopted by the NIO and was not different from those who were not included 
in the trial. Radiopharmaceutical (80 Mbq 99m Tc labelled nanocolloid, particle size: 50-800 
nm) was injected to the intratumoural area or periareolar tissue on the day before surgery. If the 
lymphoscintigraphy was unsuccessful, 2-3 ml of periareolar Patent blue 25 mg/ml® dye 
injection was applied 10 minutes before the operation. 
Patients then underwent a wide excision or mastectomy and axillary SLNB followed by 
ALND instantly if the SLN was positive by intraoperative imprint cytology or as a second 
operation if the SLN was positive only by histological examination. If isolated tumour cells or 
micrometastases were found in the SLN (n=33), ALND was omitted. 
The subregional localisation of the SLN(s) was identified and recorded on a 
standardised data sheet by the operating surgeons immediately after biopsy in the operating 
theatre (Figure 1). The harvested SLNs were separated and labelled with their localisation for 
pathological processing. Imprint cytology was performed intraoperatively, and if the result was 
positive, the operation was completed with ALND. Postoperatively, all the removed lymph 
nodes were meticulously examined by the pathologists according to the guidelines [66, 67]. In 
cases of false negative SLNB, the subregional localisation and the number of metastatic lymph 




RT and coverage simulation 
Following BCS, all patients had 3D-conformal RT. Patients were placed supine with 
both arms up and both hands holding on to a support during CT simulation. CT scan images 
with 5-mm sections were obtained. The breast was irradiated with two opposing tangential 
fields with 6 MV photons. STgF margins were determined by palpation of the breast 
parenchyma with the addition of a 1-2-cm margin in all directions. The superior borders of 
these fields intended to treat the breast only, without regard to nodal coverage. Approximately 
2 cm (max. 3 cm) of the lung was included in the posterior aspect of the field. In node-positive 
patients, an additional field was also used to deliver an effective dose to the axillary apex and 
clavicular fossa. The total dose of the whole breast and supraclavicular fossa was 50 Gy (25x2 
Gy). Breast irradiation was given via STgFs. The STgF upper margin was generally the base (± 
1 cm) of the clavicle. Retrospectively, for the purpose of this study in 61 randomly selected 
node-positive patients treated with breast-conserving therapy in whom the SLNs were found in 
the anterior or posterior axillary subregions (Level I), HTgFs were simulated using the same 
CT data. HTgF consisted of a superior border placed at the inferior edge (or below maximum 
2 cm) of the humeral head. Before RT planning, axillary volumes (Levels I, II and III) were 
contoured using the Radiation Therapy Oncology Group (RTOG) contouring atlas [68]. 
Coverage of the axillary volumes by tangential fields was classified according to the tangential 
field-planning target volumes (Levels I, II and III) overlap: 100% overlap (complete coverage), 
<100% overlap (partial coverage), and 0% overlap (lack of coverage: out of field). Examples 
of coverages are given in Figure 2. 
Statistical analysis 
All the collected data were registered in the institutional database and statistically 
analysed using Fisher’s exact test. P-values less than 0.05 were considered statistically 
significant. Statistical analysis was performed using Statistica 12.0 software (StatSoft, Tulsa, 






(a) Coverage with standard tangential field (red square). Yellow lines = Level I volumes: inner 
line - clinical target volume; outer line - planning target volume; partial coverage. Purple line 
= Level II clinical target volume; partial coverage. Blue line = Level III clinical target volume; 
no coverage, out of field 
(b) Coverage with high tangential field (red square). Yellow lines = Level I volumes: inner line 
- clinical target volume; outer line - planning target volume; complete coverage. Purple line = 
Level II clinical target volume; partial coverage. Blue line = Level III clinical target volume; 
partial coverage 
3.2. The comparative study of areola-sparing mastectomies versus nipple-sparing 
mastectomies to analyse of the oncological and cosmetic importance of the components of 
the nipple-areola complex 
This single-centre retrospective comparative study was performed between April 2013 
and December 2018 at NIO, based on the prospectively led institutional database. The study 
was approved by the institutional ethics committee board and involved a total of 251 female 
patients (ASM (n=147) or NSM (n=104)). 
The diagnosis of breast cancer, additional staging examinations, adjuvant treatments, 
and follow-ups were performed according to an institutional protocol based on the European 
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Society of Medical Oncology (ESMO) and on the European Society for Radiotherapy and 
Oncology (ESTRO) guidelines [64, 70, 71]. 
The indication for mastectomy was either therapeutic for breast cancer or prophylactic 
for patients with BRCA mutation. Both ASM and NSM operations were performed with exactly 
the same indications as those used for therapeutic procedures: based on the actual guidelines, 
ASM was the technique first applied at our department, while it was subsequently replaced in 
our daily practice by NSM after its international acceptance [41, 43]. 
Surgical technique 
All the procedures in both groups were performed by the same qualified breast surgeons 
(European Board of Surgery Qualification, (EBSQ)) based on the decisions of the breast 
multidisciplinary team with exactly the same delayed-immediate implant-based breast 
reconstruction techniques [72]. 
In the case of ASM, the whole mammary gland was dissected in a standardized way 
with an electrosurgical device using an infero-lateral incision. After the complete mobilization 
of the glandular tissue from the chest wall muscles and the subcutaneous tissue along the 
superficial fascia, a circumferential incision was made around the nipple base allowing the 
complete excision of the mammary gland with the nipple attached to the breast tissue. The 
major pectoral and serratus anterior muscles were dissected and elevated from the chest wall, 
and a Mentor Smooth Round Tissue Expander with a remote injection valve (size 400 – 550 – 
700 ml) was placed and inflated (to an average of 40 ml) in the previously prepared sub-
muscular pocket. After the closure of the submuscular pocket by stitching to the lateral edge of 
major pectoral and serratus anterior muscles, the subcutaneous and skin layers were closed with 
continuous subcutaneous and intradermal sutures. The expander implant was gradually inflated 
during the routine follow-up visits. The expander implant replacement with permanent implants 
and the contralateral symmetrisation was performed 3-14 months later depending on the 
completion time of the adjuvant treatments. The nipple was reconstructed using local flaps as 
an outpatient procedure after an additional 3-9 months. 
For NSM, the same infero-lateral incision and standardized dissection technique was 
applied. To assess the surgical margins below the NAC, after the excision of the mammary 
gland, a biopsy (“coring”) was taken from the posterior aspect of the nipple and was sent as a 
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separate specimen for postoperative histological analysis. If the pathological examination of 
that intramamillary tissue sample or the removed mammary gland, in the case of ASM, was 
positive, the NAC was excised, and the patients (ASM: n=2; NSM: n=3) were excluded from 
the study. If the surgical margin was clear, the nipple was spared followed by breast 
reconstruction with a submuscular expander implant and the implant was replaced and 
symmetrisation was performed later as described above. 
Treatment of axilla and RT 
For the axillary staging SLNB was performed. After 1 January 2015, axillary clearance 
was omitted in patients with limited axillary metastases, according to the criteria of the 
ACOSOG Z0011 trial [24, 25]. In selected cases, patients with metastatic axillary SLN were 
treated with axillary and supraclavicular RT. 
Postmastectomy radiotherapy (PMRT) in node-positive patients was always 
recommended for high-risk patients with one to three positive axillary lymph nodes, 
furthermore involved resection margins, four or more involved axillary lymph nodes and T3–
T4 tumours independent of the nodal status [64, 71]. Doses used for local and/or regional 
adjuvant irradiation were 50 Gy in 25 fractions of 2.0 Gy. 
Assessment of complications, aesthetic outcomes and quality of life 
Postoperative complications were assessed by applying the Clavien-Dindo classification 
system [73, 74]. Minor, asymptomatic complications (e.g., infections, haematomas or 
suffusions, seromas, partial skin/NAC necrosis, rippling, wound dehiscence and lymphedema 
(redness of the skin)) without need for medical therapy or surgical intervention were considered 
Grade I, while the same complications treated with antibiotics or minor interventions (e.g., 
suture of wound dehiscence, chronic seroma puncture) were considered Grade II complications. 
Any complications (e.g., haematoma, chronic infections, full thickness skin/NAC necrosis, 
implant loss and wound dehiscence) requiring invasive surgical procedures were classified as 
Grade III. Life-threatening complications or patient death were categorized as Grade IV and V 
complications, respectively. 
For the assessment of the aesthetic outcomes, a 5-point Likert scale (score: 1, strongly 
disagree; 2, disagree; 3, undecided; 4, agree; 5, strongly agree) was applied [75]. The evaluation 
was performed by a committee of 3 breast surgeons (who were not involved in the surgical 
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procedure) by reviewing the whole series of photo documentation and individually scoring each 
patient six months after the operation. 
The BREAST-Q validated patient-reported outcome measure (PROM) reconstruction 
module version 2.0 postoperative questionnaire was applied to measure the quality of life (QoL) 
of the patients [76]. Selected scales were used to measure satisfaction with the breast and 
psychosocial, physical and sexual wellbeing. The BREAST-Q questionnaire was administered 
to the patients 6 months after surgery. The patients’ responses to each item on the scale were 
transformed using a scoring conversation table. The results ranged from 0-100, with higher 
scores reflecting higher satisfaction or better QoL. 
All the collected data were registered in the institutional database and statistically 
analysed [69]. P-values less than 0.05 were considered statistically significant. 
3.3. The questionnaire study of evaluation of the needs of Hungarian breast cancer 
patients for modern oncoplastic breast surgical treatment 
This study was conducted enrolling 500 patients who underwent mastectomy and the 
breast reconstruction was either done at the same time as the removal of the primary tumour 
(immediate) or started (e.g. by implantation of a tissue expander) and completed in the second 
session (delayed-immediate breast reconstruction) between January 2015 and December 2017 
at the NIO. The study and the questionnaire was approved by the institutional ethical committee 
board and does not infringe the requirements of the Declaration of Helsinki and Tokyo [77]. 
The diagnosis of breast cancer, additional staging examinations, adjuvant treatments and 
follow-ups were performed according to the current international guidelines applied by the NIO 
[71, 78, 79]. The operations were performed by experienced and internationally qualified breast 
surgeons (EBSQ) and plastic surgeons based on the decisions of the institutional 
multidisciplinary team. 
Questionnaires were distributed to patients the day before breast surgery and were 
completed voluntarily and anonymously prior to the intervention. 
Following questions on age, highest level of education, and marital status, the 
questionnaire contained eleven structured questions to measure the emotional and mental 
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condition and attitudes related to the loss and reconstruction of breast, the expectation of 
cosmetic outcome, the qualification of the operating surgeon and the demands for the health 
care system and funding (Table 1). 
The answers and their social context was statistically analysed using Fisher’s exact and 
Chi-squared tests [69]. P-values less than 0.05 were considered statistically significant.  
Table 1. A structured questionnaire of the survey of the oncoplastic care and the answers 
received 
1. How much are you disturbed by breast loss and its aesthetic deformity on a scale of 1-10?? 
(1-no disturbance - 10-terrible disturbance) 
n mean median 
standard 
deviation (SD) 
495 8 9 3 
missing data = 5 (1%) 
2. When do you undergo breast reconstruction? 
Months or years after tumour removal Simultaneously with tumour removal 
167 (33%) 307 (61%) 
missing data = 26 (5%) 
3. What you realistically expect from breast reconstruction? 
"some kind" of breast a pretty décolletage in 
brassiere 
more beautiful 
breast, than before  
perfect breasts 
46 (9%) 194 (39%) 140 (28%) 99 (20%) 
missing data = 21 (4%) 
4. To what extent can you realistically accept symmetry at the end of breast reconstruction? 
My natural breasts were not 
symmetrical either, so it does 
not matter if my reconstructed 
breasts are not the same 
Let my reconstructed 
breasts be roughly 
the same in a dress 
or brassiere 
Let my reconstructed 
breasts be pretty 
much the same naked 
Only perfect 
symmetry is 
acceptable for me 
12 (2%) 105 (21%) 348 (70%) 32 (6%) 
missing data = 3 (1%) 
5. How many surgeries under general anaesthesia would you take maximally to have your breast 
reconstructed?  
Maximum two Maximum 3 to 4 Maximum 5 to 6 Any 
217 (43%) 184 (37%) 25 (5%) 67 (13%) 
missing data = 7 (1%) 
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6. In your opinion, how many “state-funded” reconstructive procedure is appropriate for an 
insured patient, known that sources are not endless? 
Maximum two Maximum 3 to 4 Any 
107 (21%) 220 (44%) 157 (31%) 
missing data = 16 (3%) 
7. What is your opinion regarding the change of your reconstructed breast over time (by aging)? 
Does not need further 
surgery, because it is a 
natural process 
 It is a natural 
process, that will be 
an individual 
aesthetic issue 
Even decades later, I consider it reconstructive 
surgery and not aesthetic surgery 
71 (14%) 275 (55%) 139 (28%) 
missing data = 15 (3%) 
8. Would you agree to have your breast reconstruction performed by a general surgeon instead 
of a plastic surgeon? 
Yes No 
40 (8%) 448 (90%) 
missing data = 12 (2%) 
9. In your opinion, who should perform the modern surgical procedures of breast cancer 
treatment (oncoplastic surgery, breast reconstruction) in Hungary? 
General surgeon, as 
usually in our country 
Gynaecologist, as 
sometimes in our 
country 
Plastic surgeon Specially trained breast 
surgeon with the 
involvement plastic 
surgeon, if needed 
5 (1%) 3 (1%) 54 (11%) 430 (86%) 
missing data = 8 (2%) 
10. In your opinion, how acceptable is it that in Hungary, in the 21st century, only one or two 
hospitals have specially prepared, modern breast surgical centres / units? 
As good as it is now It's unfortunate, but 
that’s it 
It is very 
unfortunate, but 
who wants better 
goes to private care 
Unacceptable, modern 
specialized breast surgery 
should be provided 
2 (1%) 51 (10%) 46 (9%) 394 (79%) 
missing data = 7 (1%) 
11. Do you think that being operated by a breast surgeon has a significant effect on your 
recovery? 
Does not affect Affects Strongly affects One of the most important 
14 (3%) 54 (11%) 111 (22%) 316 (63%) 





4.1. The retrospective cohort study of the mapping of the functional anatomy of lymphatic 
drainage to the axilla in early breast cancer 
A total of 933 women were enrolled in the study. The mean age of the patients was 64.1 
years (range 19 to 91 years, median: 64 years). Three women were excluded because the breast 
tumour was larger than 5 cm according to the postoperative pathologic examination. Another 
two patients were ruled out due to newly discovered lympho-proliferative disorders affecting 
the axillary lymph nodes. Another 58 patients were discarded because of an uninterpretable 
sentinel data sheet or incomplete clinical-histological data. 
The detailed pathologic characteristics of the primary breast tumours are summarised in 
Table 2. 
Table 2. Pathological characteristics of the primary breast tumour 
 
pT n % 
pTis 104 11.8 
pT1mi 3 0.3 
pT1a 31 3.5 
PT1b 95 10.8 
pT1c 316 36.0 
pT2 300 34.1 
pT3 30 3.4 
Grade (invasive tumours) 
I 180 23.4 
II 370 48.1 
III 219 28.5 
Grade (in situ carcinomas)   
Low 28 26.9 
Medium 50 47.8 
High 26 25.3 
Receptor status 
ER 751 80.5 
PR 641 68.7 
Her2 72 7.7 
Molecular subtype 
Luminal A 438 59.4 
Luminal B 171 23.2 
Luminal B-Her2+ 41 5.6 
Non-luminal 73 9.9 




Present 322 39.3 
Not present 497 60.7 
Histological type 
Invasive ductal carcinoma 643 73.1 
Invasive lobular carcinoma 99 11.3 
Other invasive 34 3.9 
DCIS 75 8.5 
LCIS 16 1.8 
Other in situ 13 1.5 
Palpability 
Palpable 499 55.9 
Not palpable 393 44.1 
Mitotic activity 
<11 539 67.0 
11-20 157 19.5 
20< 109 13.5 
Type of breast surgery   
Mastectomy 371 39.8 
Breast conserving surgery 562 60.2 
SLN positivity   
SLN-negative patients 744 79.7 
SLN-positive patients 189 20.3 
Total removed SLNs 1538 - 
SLNs removed per operation 1.6 - 
ALND   
Total number of ALND 156 16.7 
Total number of removed lymph nodes 2109 - 
Lymph nodes removed per ALND 13.5 - 
Positive lymph nodes per ALND 406 19.3 
Regarding the location of the breast cancer, 44.7% (n=417) were in the upper-outer, 
14.7% (n=137) in the upper-inner, 9.9% (n=93) in the lower-outer, 6.7% (n=63) in the lower-
inner quadrant, and 2.8% (n=27) in the axillary process (tail of Spence); 12.8% (n=119) were 
central tumours and 3.5% (n=33) were multiplex. 
There was a significant correlation between the location and the molecular subtype of 
the tumour (p=0.022). Non-luminal tumours were mainly localised in the upper quadrants 
(84.6% n=11). Similarly, the triple negative subtype was also likely to appear in the upper-outer 
quadrant (57.1%; n=40). However, cancers in the lower-inner quadrant were mostly Her2-




Table 3. Correlation between molecular subtype (column) and the location (row) of the primary 
breast tumour (p=0.022) 
 
 
Luminal A Luminal B LumB – Her2 Non-luminal 
Triple 
negative 
n % n % n % n % n % 
Upper-outer 210 49.3 73 44.0 18 43.9 7 53.9 40 57.1 
Upper-inner 65 15.3 39 23.5 5 12.2 4 30.8 9 12.9 
Lower-outer 47 11.0 20 12.1 4 9.8 0 0 9 12.9 
Lower-inner 36 8.5 13 7.8 7 17.1 0 0 1 1.4 
Central 62 14.6 17 10.2 7 17.1 2 15.4 6 8.6 
Axillary process 6 1.4 4 2.4 0 0 0 0 5 7.1 
The tracer for lympho-scintigraphy was injected intratumourally and periareolarly in 
38.8% (n=362) and 57.6% (n=537) of the cases, respectively. We used only 
radiopharmaceutical (80 Mbq 99m Tc labelled nanocolloid) in 86.9% (n=811), Patent blue dye 
in 4.4% (n=41) and both in 4.8% (n=45) of the cases. 
None of the examined characteristics of the primary breast cancer (molecular subtype 
p=0.360) had significant correlation with the subregional localisation of the SLN. 
We divided our study population into two groups based on the injection site and 
analysed the relationships between the location of the SLN and location of the primary breast 
tumour. In case of intratumoural application, we found significant correlation between the 
location of the breast cancer and the subregional location of the SLN (p=0.016). However, 
examining only the histologically positive SLNs, the relationship between their location and 
the primary tumour location was not statistically significant (p=0.674). 
If periareolar injections were used, the location of the SLN was not dependent on the 
location of the primary breast tumour (p=0.398), whilst the correlation between the location of 
the positive SLN and the location of the breast cancer was statistically significant (p=0.039). 
(Table 4.) 
According to our data, tumours in the upper-outer quadrant are most frequently drained 
to the anterior subregion (34.2%). Posterior subregion receives lymph mainly from the upper-
outer quadrant (31.6%) and the axillary process (36.3%), whereas the inner and central 
quadrants have very similar drainage patterns with a tendency to give efferent lymphatics more 
often to the anterior (53.9%, 69.6% and 54.5%) and central (28.8%, 26.1% and 22.7%) lymph 
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nodes. The central lymph nodes receive lymphatic drainage equally from the different quadrants 
of the breast. (Table 4.) 
 An average of 1.6 (range: 1-8, median: 1) SLNs were harvested per operation, and the 
SLN positivity rate was 20.3% (n=189). 
We also analysed the distribution pattern and metastatic status of the SLN in the 
subregions of the axilla (Table 4.). The most common site of the SLN was the anterior subregion 
(39.9%; n=349), while the least common was the apical subregion (3.4%; n=30). In contrast, 
the positivity rate was higher in the apical subregion (30.0%; n=9) than in the anterior subregion 
(20.9%; n=73). The SLN was present in the lateral subregion in 5.5% (n=48) of the cases. Of 
these 48 lymph nodes, 11 SLNs - 1.3% of the total cases - were positive. In the central and 
posterior subregions, 53 (6.1%) and 43 (4.9%) SLNs, respectively, were found to be positive 
out of the 245 (28.0%) and 203 (23.2%) removed lymph nodes, respectively. 
In 91.1% (n=797) of the cases, the SLN appeared in the anterior, posterior or central 
subregions, corresponding to Level I and II zones (Table 4).  
Table 4. Correlation between the location of the primary breast tumour (column) and the 
subregional location of the SLN (row) if intratumoural injections were used (p=0.016) and 
distribution pattern and metastatic status of the SLN in the subregions of the axilla 
 
 
In 503 patients, the SLN was located within the anterior or posterior subregion (Level 






































































































treated with RT in our Institute. Sixty-one women were subjected to WBI. The coverage of 
axillary volumes by tangential fields is given in Table 5. There was a significant difference 
between the two plans regarding the coverage of the Level I axillary volume. HTgF increased 
the rate of complete coverage from 0% to 65.6% (40 of 61; p<0.0001). Concerning the Level 
II volume, the rate of complete coverage with STgF or HTgF was 0% and 6.6% (4 of 61), 
respectively (p=0.1198). The rate of “out of field” cases was very high with STgF, 72.1% (44 
of 61), but “out of field” cases were not observed with HTgF irradiation (p<0.0001). The 
coverage of the Level III volume was very poor (rate of “out of field” with STgF or HTgF: 
91.8% and 9.8%, p<0.0001).  
Table 5. Coverage of axillary volumes by tangential fields (n=61) 
% (No.) STgF HTgF p-value 
Level I 
Complete 0 (0) 65.6 (40) < 0.0001 
Partial 100.0 (61) 34.4 (21) - 
Out of field 0 (0) 0 (0) - 
Level II 
Complete 0 (0) 6.6 (4) 0.1198 
Partial 27.9 (17) 93.4 (57) - 
Out of field 72.1 (44) 0 (0) < 0.0001 
Level Complete 0 (0) 0 (0) - 
III Partial 8.2 (5)  90.2 (55) - 
 Out of field 91.8 (56) 9.8 (6) < 0.0001 
 
4.2. The comparative study of areola-sparing mastectomies versus nipple-sparing 
mastectomies to analyse of the oncological and cosmetic importance of the components of 
the nipple-areola complex 
Eight patients were excluded from the study due to lost follow-up or incomplete 
clinicopathological data; eleven women from both groups were excluded because of previous 
breast surgery, and five patients (ASM: n=2; NSM: n=3) were omitted from further evaluation 
because of positive nipple-areola margins requiring NAC resection. As a result, a total of 134 
and 93 patients were enrolled and underwent ASM and NSM, respectively. 
Detailed patients and tumour characteristics are summarized in Table 6 and Table 7, 
respectively.   
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Table 6. Patient characteristics of the ASM and NSM groups. 
 ASM NSM p 
Number of patients 134 93  
Age (years)    
median (min. – max.) 41 (26 – 64) 40 (26 – 70) 0.365 
BMI (kg/m2)  
mean ± SD 21.6 ± 3.1 21.2 ± 3.4 0.285 
Cup size n (%) n (%)  
A 23 (17.2) 7 (7.5) 
0.003 
B 75 (55.9) 62 (66.7) 
C 25 (18.7) 24 (25.8) 
D 11 (8.2) 0 (0.0) 
Indication n (%) n (%)  
therapeutic 89 (66.4) 85 (91.4) 
1.2x10-5 
prophylactic 45 (33.6) 8 (8.6) 
Operative duration 
(minutes) 
    
median (min. – max.) 80 (50 – 150) 76 (43 – 120) 0.431 
Neoadjuvant n (%) n (%)  
chemotherapy 20 (22.5) 9 (10.6) 0.244 
Initiation of adjuvant 
therapy (weeks) 
 
median (min. – max.) 7.4 (4.6 – 11.9) 8.1 (4.1 – 12.0) 0.124 






































There was no significant difference in duration of the surgical procedures between the 
two groups (p=0.431). The median time of ASM was 80 minutes (range: 50-150 minutes), while 
the NSM operations lasted for 76 minutes (range: 43-120 minutes) on average (Table 6).  
Table 7. Characteristics of the primary breast tumour and regional lymph nodes in the ASM 
and NSM groups 
 ASM NSM p 
Pathological TNM n= 89 (therapeutic) n=85 (therapeutic)  
pT n (%) n (%)  0.026 
pTis  5 (5.6)  6 (7.1)  
pT1  37 (41.6)  33 (38.8)  
pT2  23 (25.8)  19 (22.3)  
pT3  4 (4.5)  18 (21.1)  
pN  n (%) n (%)  0.900 
pN0  47 (52.8)  53 (62.3)  
pN1  18 (20.2)  19 (22.3)  
pN2  3 (3.4) 2 (2.4)  
pN3  1 (1.1)  2 (2.4)  
ypT n (%) n (%)  
ypT0 5 (5.6) 4 (4.7)  
ypT1 9 (10.2) 2 (2.4)  
ypN2 4 (4.5) 2 (2.4)  
ypN3 2 (2.2) 1 (1.2)  
ypN n (%) n (%)  
ypN0 11 (12.4) 6 (7.0)  
ypN1 7 (7.9) 2 (2.4)  
ypN2 1 (1.1) 0 (0)  




Grade (invasive breast cancer)  0.435 
I 16 (18.0) 11 (12.9)  
II 34 (38.2) 40 (47.1)  
III 39 (43.8) 34 (40.0)  


































Histological type  
Invasive ductal carcinoma 74 (83.2) 60 (70.6) 
0.349 
Invasive lobular carcinoma 5 (5.6) 11 (12.9) 
Other invasive 4 (4.5) 6 (7.1) 
DCIS 5 (5.6) 6 (7.1) 
LCIS 1 (1.1) 2 (2.3) 
Nipple – tumour distance (cm) 
median (min. – max.) 2.7 (0.6 – 7.0) 3.1 (0.7 – 7.0) 0.497 
Follow-up 45 months (range: 20.1-82.7) 
local recurrence 3 (3.4) 2 (2.4)  
distant metastatic disease 5 (5.6) 1 (1.2)  
distant metastases-related 
death 
2 (2.2) 1 (1.2)  
Axillary surgery 0.656 
Sentinel lymph node biopsy 64 (71.9) 62 (72.9)  
Axillary lymph node 
dissection 
23 (25.9) 19 (22.4)  
No axillary surgery 2 (2.2) 0  
Not reported 0 4 (4.7)  
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The recorded early postoperative complications in the two groups are summarized in 
Table 8. In total, the overall complication rate was 13.4% (n=18) for ASM and 12.9% (n=12) 
for NSM. The majority of complications were Grade I, including partial skin/NAC necrosis, 
seroma, infection or wound dehiscence, which healed spontaneously in both groups. 
Table 8. Early postoperative complications based on the Clavien-Dindo classification in the 







The mean follow-up period was 45.0 months (range: 20.1-82.7). During the follow-up 
period three distant metastases-related deaths were recorded (ASM:2.2%, n=2; NSM:1.2%, 
n=1), five local recurrences were observed in preserved areola or the nipple (ASM:3.4%, n=3; 
NSM:2.4%, n=2), while overall six distant metastatic diseases were recorded (ASM:5.6%, n=5; 
NSM:1.2%, n=1). There was no significant difference in DFS (p=0.762) and OS (p=0.601) 
between the two groups (Figure 3 and 4). 







Grade I 12 (9.0) 9 (9.7) 
 
infection 4 (3.0) 3 (3.2) 
seroma 2 (1.5) 2 (2.1) 
partial skin / NAC 
necrosis 
3 (2.2) 2 (2.1) 
rippling 2 (1.5) 1 (1.1) 
wound dehiscence 1 (0.7) 1 (1.1) 
Grade II 3 (2.2) 1 (1.1) 
infection 2 (1.5) 0 (0.0) 
chronic seroma 1 (0.7) 1 (1.1) 
Grade III 3 (2.2) 2 (2.1) 
haematoma 2 (1.5) 1 (1.1) 
implant loss 1 (0.7) 1 (1.1) 















































Figure 3. Kaplan-Meier curve showing DFS of the two groups 






































Figure 4. Kaplan-Meier curve showing OS of the two groups 
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The median time until adjuvant treatment initiation was 7.4 weeks (range: 4.6 – 11.9) 
for ASM and 8.1 weeks (range: 4.1 – 12.0) for the NSM group. 
Both groups had the same objective aesthetic outcomes measured by a 5-point Likert 
scale system. The majority of breast surgeons agreed with the statement that “This patient had 
an excellent aesthetic outcome”, with a median score of 4.1 (range: 2-5) in the ASM group and 
4.3 (range: 2-5) in the NSM group. 
The results of the corresponding BREAST-Q domains showed no significant difference 
between ASM and NSM patients (Table 9). The highest mean scores were observed for 
“physical wellbeing”, while the median “satisfaction with breasts” and “psychosocial 
wellbeing” scores were slightly lower. The lowest mean scores were detected for “sexual 
wellbeing”. 




mean ± SD 
NSM 
mean ± SD 
p 
BREAST-Q postop. 1  - Satisfaction with breasts 64.9 ± 21.2 67.8 ± 17.2 0.691 
BREAST-Q postop. 2  - Psychosocial wellbeing 68.4 ± 18.4 72.4 ± 17.5 0.123 
BREAST-Q postop. 3  - Physical wellbeing 80.0 ± 14.0 76.5 ± 15.5 0.232 
BREAST-Q postop. 4  - Sexual wellbeing 59.1 ± 18.3 54.0 ± 20.9 0.252 
 
4.3. The questionnaire study of evaluation of the needs of Hungarian breast cancer 
patients for modern oncoplastic breast surgical treatment 
The median age of the women was 47 years (min.-max.: 26-73). 52% (n = 260) of those 
surveyed had a higher education degree and the majority (59%; n = 294) were married. 




Table 10. Characteristics of the study population 
Age 
n mean median minimum maximum 
485 48 47 26 73 
missing data = 15 (3%) 
Highest level of education 
primary school secondary school university 
7 (1%) 218 (44%) 260 (52%) 
missing data = 15 (3%) 
Marital status 
single married divorced widow 
52 (10%) 294 (59%) 119 (24%) 20 (4%) 
missing data = 15 (3%) 
 
Understandably, breast loss significantly embarrassed the respondents, with answers 
averaging 8 ± 3 (mean ± SD) on a scale of 1 to 10; and there was no difference between the 
responses in terms of education or marital status (Figure 5). 
Immediate breast reconstruction was performed in almost two-thirds of cases (61%; n = 
307), while in 167 patients (33%), breast reconstruction was delayed-immediate; in the latter 
case the survey was done months or years after tumour removal, before the final session of the 
reconstruction. 
Based on the answers, 39% (n = 194) of the interviewed women would be satisfied with 
breasts resulting in a pretty décolletage in brassiere, however, 28% (n = 140) would like to have 
more beautiful breasts, than the original ones were, and 20% (n = 99) want perfect breasts at 
the end of the reconstruction process. In terms of expectations, there was a significant 
correlation with education: higher education was associated with higher expectations (p <0.05). 
Patients had a firm opinion regarding symmetry, there was no difference in either marital status 
or education: 70% (n = 348) of women would like roughly identical breasts naked at the end of 




How much are you disturbed by breast loss and its aesthetic deformity on a scale of 1-10?
(1-no disturbance - 10-terrible disturbance)
primary school secondary school university












































































































































































































For an optimal aesthetic outcome, 43% (n = 217) of the survey participants would 
undertake a maximum of two and 37% (n = 184) up to three or four operations. 
The funding of the interventions divided the opinions: according to 44% (n = 220) of 
the patients, the health insurance company should cover a maximum of three to four operations, 
21% (n = 107) think that a maximum of only two surgeries should be funded, while almost a 
third of the study population (31%; n = 157) are of the opinion that no matter how many 
interventions are needed, they should all be paid for by the NEAK. Women with a high school 
education are less likely to justify more surgeries from state funding, while those with a 
university degree are more likely (p <0.05). 
Fifty-five percent of patients (n = 275) believe that age-related changes in reconstructed 
breasts are an individual aesthetic plastic surgery issue, however, 28% (n = 139) share the 
opinion that even decades from the primary operation, it will be part of the oncologic 
reconstructive surgery, not an independent aesthetic surgical procedure. 
Patients have a clear view of the surgeon performing the procedure: 90% of them (n = 
448) would entrust the reconstruction to a plastic surgeon, moreover, 86% (n = 430) said that 
modern surgical care for breasts cancer should be performed by specially trained breast 
surgeons, instead of general surgeons, as currently happens. 
The vast majority of respondents (79%; n = 394) do not consider it acceptable that there 
are currently only one or two certified breast surgical centres in Hungary, whilst 10% (n = 51) 
accepts the current situation and a further 9% (n = 46) believe that it is necessary to turn to 
private care for better care. 
Almost all of the surveyed women (96%; n = 481) believe that the recovery is 
significantly influenced by whether breast surgeon performs the operation. Furthermore, 63% 







5.1. Assessing relationship between the quadrants of the breast and the subregions of the 
axilla and description of the functional and morphologic lymphatic drainage pattern – 
based on the results of study 4.1. 
In summary, we did not find a significant correlation between the histopathological 
parameters of the primary breast cancer and the subregional location of the SLN. However, it 
is obvious from the data that the SLN is more than likely to be present in the anterior, posterior 
and central axillary subregions. Moreover, the SLN positivity rate in the lateral subregion 
(22.9%; n=11) was not negligible. It is also clear from the data that upper-outer quadrant 
tumours spread least frequently to the anterior lymph nodes, while inner and central quadrant 
tumours have similar drainage patterns mainly to the anterior and central subregions.  
5.2. Assessing the coverage of the axillary volumes by standard and high tangential fields 
for whole breast irradiation and axillary reverse mapping - based on the results of study 
4.1. 
There are several studies concerning the coverage of axillary lymph nodes from whole 
breast tangential field irradiation. Reed et al. [80] reported that using STgFs, no patient received 
complete coverage of the axillary Level I–II lymph node volume. They concluded that 
definitive irradiation of the Level I and II axillary lymph node regions required significant 
modification of the STgFs. Krasin et al. [81] showed that the use of STgFs does not 
therapeutically treat the regional lymph nodes. In their series, only 1 out of 25 patients had 
adequate coverage of the Level I region, and no patient had adequate coverage of Level II. 
Reznik et al. [82] observed that adequate coverage of Level I, defined when 95% of the volume 
received 95% of the dose, was achieved in none of the patients with normal tangents and in 6 
patients (6 of 35) with high tangents. In a study by Orecchia et al. [83], the Level I nodes were 
only partially in the STgF, and the mean dose was only 48.7% of the prescribed dose. Our study 
was performed to address the issue of axillary volume coverage according to tangential field 
size. We showed that no patient had complete coverage of the Level I or Level II region with 
STgFs, and in 72.1% of the patients, the Level II volume was completely out of field. Using 
HTgF, 65.6% of the patients had complete coverage of Level I regions and the complete 
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coverage rate was only 6.6% for Level II volume. The coverage of Level III region was very 
poor either with STgF (rate of out of field: 91.8%) or HTgF (rate of out of field: 9.8%). 
Our results are consistent with the earlier studies that showed that STgF does not 
adequately cover the axillary volumes. With modern techniques, adequate coverage of the 
axillary volumes depends on the cranial field edge. Ohashi et al. [84] used 3D-CRT with a field-
in-field technique, and half of the humeral head was inside the field. With this technique, even 
the dose to the Level III region was appropriate (V90 was 82.8%). In a study by Nagar et al. 
[85], when the tangential fields were modified to include Level I and II volumes, the mean dose 
(STgF vs. modified HTgF) increased from 35 Gy to 51 Gy and 11 Gy to 50 Gy, respectively. 
In patients studied by Belkacemi et al. [86], the STgF was defined with the cranial border set at 
2 cm below the humeral head, while the HTgF consisted of a superior border placed at the 
inferior edge of the humeral head. The mean dose delivered to Level I with STgF or HTgF was 
20 Gy and 33 Gy, respectively (p<0.0001). We also used classical HTgF such as Belkacemi et 
al. [86], and the coverage of the Level I region was limited (complete coverage rate 65.6%). 
Attempts to increase the volume of complete coverage could induce a significant increase in 
lung dose. Alco et al. [87] suggested shaping the tangential field with multi-leaf collimators 
according to axillary level volumes to ensure complete coverage, but the inclusion of the 
axillary region in the target volume increased the irradiated lung volume. Mean lung dose was 
with the HTgF or multi-leaf collimators HTgF 6.5 and 9.6 Gy, respectively (p=0.0001). To 
study the adequate coverage of the axilla, Levels I, II and III should be defined (delineated) by 
anatomical structures. STgFs provide limited coverage of the axilla, but HTgFs may provide 
complete coverage of Level I volume in some patients. 
In our study, 9 (1.0%) positive SLNs were in the apical and 11 (1.3%) metastatic lymph 
nodes were in the lateral subregions. In total, 20 patients with positive lymph nodes (2.3% of 
our cases) would be left untreated if we applied tangential WBI to treat the axilla. 
In our view, for the proper treatment of the axilla, an additional axillary and 
supraclavicular RT field is needed. This correlates with the findings of the Hungarian 
OTOASOR prospective randomised clinical trial with axillary and supraclavicular field 




5.3. Assessing the sentinel lymph node positivity rate in the lateral, undissected subregion 
when the axillary reverse mapping technique is applied - based on the results of study 4.1 
Applying the ARM technique, the lymph nodes stained with blue dye or radioisotope 
are preserved to prevent postoperative lymphedema. The subregional localisation of the ARM 
nodes has not yet been clearly identified, but it seems obvious that majority of the lymphatics 
draining the upper limb traverses deep in the axilla [30]. This was also confirmed by Ikeda et 
al. [89], who found ARM nodes in zones that correspond to mainly the lateral, apical and 
posterior axillary subregions. 
In our study, 281 (32.1%) SLNs were found within one of these subregions, and 22.4% 
(n=63) of them were positive. This means that 7.2% of all our cases had one positive lymph 
node in the expected ARM lymph node regions. 
According to these results, due to the high rate of posterior subregional SLN drainage 
(21.8% n=203) and SLN positivity (21.2%), not only the ALND but also the SLNB carry a high 
risk of a preserved positive lymph node and have a negative effect on the patient’s successful 
treatment. This corresponds to the results that showed that the oncological safety of the ARM 
technique in patients with axillary lymph node metastasis from breast cancer is questionable 
[90, 91], and proper indications, patient selection and further investigations are needed for the 
safe application of ARM [92]. 
5.4. Analysing the oncological and cosmetic importance of the nipple-areola complex 
versus its components, the nipple and the pigmented skin of the areola – based on the 
results of study 4.2. 
In recent years, NSM has become the primary mastectomy technique for prophylactic 
and therapeutic breast cancer surgical treatment [13]. Several reviews have been published 
regarding its indications, oncological safety and aesthetic outcomes [40-42]. Tuosimis et al. 
summarizing the results of three studies with a total of 838 patients, described the ideal 
candidate for NSM as a patient with A- or B-cup breast size, no ptosis and a BMI < 30 kg/m2. 
Regarding their conclusion, the only absolute contraindications were nipple involvement and 
inflammatory breast cancer [42]. Mallon et al. focused on oncological safety and reported an 
overall nipple recurrence rate of 0.9% and an overall skin flap recurrence rate of 4.2% [41]. 
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They also examined the complication of nipple necrosis. According to their data, full-thickness 
necrosis was 2.9%, while partial-thickness nipple necrosis was present in 6.3% of the cases 
[41]. Headon et al. also assessed the complications by a pooled analysis of 12.358 patients from 
studies published between 1970 and 2015. They found that the overall complication rate was 
22.3% and the nipple necrosis rate was 5.9%. Reviewing 73 studies, Headon et al. reported a 
pooled locoregional recurrence rate of 2.39% [93]. Regarding aesthetic results, Didier et al.’s 
questionnaire study found that NSM was significantly better than SSM for body image, 
satisfaction with nipple appearance and sensitivity and feeling of mutilation [94]. 
After the international acceptance of NSM in the field of breast cancer surgery, the 
implementation of SSM has declined significantly. Several papers are analysing the oncological 
safety, feasibility and possible indications of SSM in breast cancer surgery [40, 95], but 
significantly less similar studies are available for ASM in the international literature. However 
as reported by Simmons et al., ASM seems to have similar oncological safety, based on the 
examined 217 mastectomy specimens. The authors reported areola involvement in only 0.9% 
(n=2) of the cases [96]. Banerjee et al. obtained exactly the same results and found 2 cases of 
areola involvement out of 219 mastectomy specimens [97]. 
The present study did not find significant differences in oncological safety between 
ASM and NSM. The local recurrence rates were 3.4% (n=3) and 2.4% (n=2) in the ASM and 
NSM groups, respectively. Significant difference was not proven in DFS (p=0.762) or OS 
(p=0.601) between the two groups. 
Other studies by Simmons et al. examining 17 patients with ASM and immediate breast 
reconstruction reported one postoperative complication (localized wound infection) and no 
locoregional recurrence in the 2-year-long follow-up period with excellent aesthetic outcomes 
superior to those of SSM [95, 98, 99]. The operation times in our study were almost equal (80 
and 76 minutes) for both procedures. Moreover, the majority of the complications were minor 
(Grade I) for both ASM (n=12; 9.0%) and NSM (n=9; 9.7%), while the reoperation rate (Grade 
III complications) was only 2.2% (n=3) and 2.1% (n=2) for ASM and NSM, respectively. 
Areola necrosis was present in 2.2% (n=3) of ASM cases, while NAC necrosis was detected in 
2.1% (n=2) of NSM cases. Regarding the initiation of adjuvant treatment after surgery, 
Harmeling et al. by reviewing fourteen studies of 5.270 patients found that mean time from 
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mastectomy with immediate breast reconstruction to adjuvant therapy varied between 29 and 
61 days [100]. Albright et al. retrospectively analysed 129.951 cases comparing NSM to SSM 
and reported that NSM was not associated with a delay in delivery of adjuvant chemotherapy 
or hormonal therapy compared to SSM [101]. In the present study, the adjuvant treatment was 
initiated within 12 weeks after surgery (ASM:7.4 weeks (range: 4.6 – 11.9); NSM: 8.1 weeks 
(range: 4.1 – 12.0)) in all of the cases in both groups.  
Weber et al. reported the recommendations of the Oncoplastic Breast Consortium 
consensus conference on NSM, which currently provides the highest level of evidence of NSM 
application [13]. The expert panel of 44 breast surgeons from 14 countries on four continents 
agreed that NSM is comparable to conventional mastectomy without reconstruction and to BCS 
and SSM if cases are selected appropriately. Regarding their recommendation for indications, 
NSM can be performed for any tumour size without skin or NAC involvement independent of 
axillary status and for DCIS; NSM is also applicable in risk-reducing settings. There was a 
strong consensus that nipple involvement and R1 resection at the nipple margin are 
contraindications for nipple preservation. However, the panel was divided in regard to the 
question of nipple excision with areola preservation if the retroareolar margins were positive. 
They also noted a 0.81% (n=7) nipple recurrence rate after NSM in a follow-up period of 32 
months. The consensus conference concluded that further randomized trials and longer follow-
up periods are needed to provide missing evidence and to clarify indications to guide treatment. 
The indications for both ASM and NSM in this study were primarily based on 
theoretical considerations strictly according to the actual international guidelines, not purely on 
the nipple-tumour distance [13, 41]. Therefore, ASM operations were performed first in this 
study and replaced by NSM when it was internationally accepted for both prophylactic and 
therapeutic indications [41]. This resulted in two homogenous study groups, enabling the 
comparison of the two surgical techniques. 
5.5. Assessing the opinions and needs of the Hungarian breast cancer population about a 
modern breast reconstruction system - based on the results of study 4.3. 
The spread of the modern oncoplastic approach has resulted in a paradigm shift in breast 
cancer treatment [102-104]. Surgical treatment has shifted from breast tumour excision to a 
complex surgical process including complete breast reconstruction, even bilateral or a series of 
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operations. This poses a number of system-level tasks, such as the need for lifelong plastic 
surgical follow-up of reconstructed breasts and the necessary cosmetic corrections in parallel 
with oncological controls. These needs and indications are new in breast cancer care, the precise 
definition of which, the clarification of the scope of care and the requirements of material and 
human resources are essential for the development and high-level long-term operation of a 
modern patient-centred care system. The basis of all is formed by the recognition and 
analysation of the needs and expectations of patients. 
The present study assessed the systemic needs and expectations of female patients who 
underwent breast loss and breast reconstruction. It is clear from the results that breast loss 
significantly disturbs female patients regardless of education and marital status (Figure 5). 
These findings correspond to the results of a questionnaire survey of 500 female patients 
between 2010 and 2011 published by our working group in 2014 [103]. According to the study, 
30% (n = 148) of patients were moderately and 40% (n = 198) were very afraid of breast loss, 
nearly 50% (46%; n = 224) wanted reconstruction, but they knew almost nothing (32%; n = 
158) or very little (56%; n = 279) about it [103]. Based on oncoplastic breast surgery at the 
NIO, according to a repetition of the same questionnaire survey conducted in 2017-2018, 
women are still equally afraid of breast loss, but in contrast to the previous data (10%; n = 48), 
30% of the respondents (n = 152) were already aware of the possibilities of breast 
reconstruction, which information was collected mainly from the surgeon (52%; n = 258) or the 
internet (27%; n = 135). Based on these, it can be generally stated that breast loss places a 
significant psychological burden on breast cancer patients regardless of social status and 
education, therefore, the extension of the oncoplastic care system is needed and necessary in 
Hungary. In the last 6-8 years, the oncoplastic approach has become widespread and well-
known among Hungarian women. In parallel, the population's demand for this special health 
service is also growing, which the health care system must be able to provide. 
Patients have high expectations for the aesthetic outcome of the operations, in total, 
almost half of the women (48%; n = 239) want more beautiful (28%; n = 140) or perfect (20%; 
n = 99) breasts at the end of the reconstruction process. Preoperative patient information on 
realistic expectations is one of the top priorities, because oncoplastic procedures are not 
aesthetic operations, and albeit they are often capable of the same high level of results as 
aesthetic surgeries due to their technique, but are completely subordinated to oncological 
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procedures and principles (e.g. resection site, extent, RT, etc.), thus, their effectiveness is 
influenced by a number of other factors beyond plastic surgery [105]. 
The majority of the surveyed female patients (70%; n = 348) would like to have roughly 
identical breasts naked at the end of the reconstruction surgery, regardless of marital status or 
education. Given that the structure of the two breasts differs during the most frequently applied 
implant-based post-mastectomy reconstructions, breast asymmetry will increase over time, 
since the lifted own healthy breast will behave differently due to its biological properties than 
an implant-only breast. Based on this, patients have secondary surgical demands due to changes 
in symmetry over time. 
According to the surveyed women, the desired high cosmetic result would like to be 
achieved by two, but not more, than three or four operations, which, in their view, should be 
covered by the NEAK. On the one hand, it is necessary to avoid oncology-funded aesthetic 
surgeries in the future, which also raises ethical and professional issues that are difficult to 
resolve, on the other hand, treatment consisting of a series of operations is a huge load on the 
care system - as if the number of surgeries for annual breast cancer had increased by hundreds 
or thousands of cases. At present, the system is able to provide this in elements, but it is 
questionable whether it would be able to ensure in total. Therefore, the joint work of patients, 
profession and professional policy is essential and needed. 
Patients would entrust their surgical treatment in specialized centres to specially trained 
breast surgeons, because, in their opinion, this would have a significant impact on their 
recovery. In the treatment of breast cancer, the breast surgeon is also an independent prognostic 
factor [106], but the spread and quality assurance of BUs in Hungary and with BRESO 
accreditation, the survival as well as the QoL of patients can be further improved in the 21st 
century [47].  
The need for oncoplastic breast reconstruction following mastectomy in Hungary is in 
line with international trends: according to a British study, 50% of female patients awaiting 
breast removal [107], while according to a French study by Ananian et al., 81% of respondents 
would like to have reconstruction [108]. Similar to the international situation, according to our 
survey, the main source of information for Hungarian patients is also the surgeon and the 
internet [109, 110]. Understanding the needs of the affected women, providing adequate 
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information, increasing accessibility, organizing patient routes and properly structuring the 
health care system are essential for a high level of expansion of oncoplastic breast cancer care 




6.1. Our findings suggest that there is no significant correlation between the 
histopathological parameters of the primary breast tumour and the subregional 
localisation of the SLN. 
The majority of SLNs are located in the anterior and central subregions. 
6.2. When primary RT is used to treat the axilla, the contouring of the axillary lymph 
node levels is necessary for the proper design of the tangential field borders. Our analysis 
leads to the conclusion that STgF did not provide complete coverage of level I-II axillary 
lymph nodes. 
Tangential field WBI provides limited coverage of the axilla. The use of HTgFs is one 
means of improving axillary coverage with WBI. Only 65.6% of our patients had complete 
Level I coverage with HTgFs. In line with previous studies, additional axillary and 
supraclavicular RT field should be considered to treat the axilla properly. 
6.3 Applying the ARM technique and leaving lymph nodes behind in the apical, lateral or 
posterior axillary subregions may leave behind up to 7.2% of metastatic lymph nodes, 
which may elevate the risk of possible understaging or undertreatment. 
In these cases, clipping the preserved lymph nodes should be mandatory for adjuvant 
axillary RT. 
6.4. Based on our previously discussed results, there is no significant difference in 
oncological safety, complications, aesthetic results or patient satisfaction between ASM 
and NSM. Preservation of the nipple doesn’t make oncological difference, while 
preserving breast projection and natural pigmented skin envelope of the areola seems to 
have the same importance than the complex NAC itself, resulting in the same cosmetic 
outcome and patient satisfaction like NSM's. 
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Moreover, preferring ASM over SSM means that the breast projection remains 
unchanged, and there is the possibility of nipple reconstruction from the expanded pigmented 
skin of the areola, resulting in a more natural-appearing NAC. Therefore, ASM could be a 
suitable treatment option, if NSM is not oncologically feasible. Further prospective randomized 
studies and long-term follow-ups are needed to support our findings. 
6.5. The modern oncoplastic care raises new, complex, systemic professional questions 
and issues in oncology and reconstructive surgery, which result in new challenges and 
tasks of patient information, human resource training, care system capacity assessment 
and funding. 
Breast cancer patients want state-of-the-art surgeries performed by qualified breast 
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Introduction: The aims of this study were to investigate the correlation between lymphatic drainage and
the sentinel lymph node (SLN) status of the subregions in the context of the clinic-pathological pa-
rameters of the tumour and the coverage of the axillary volumes by standard and high tangential fields
(STgF and HTgF) for whole breast radiotherapy and axillary reverse mapping (ARM).
Patients and methods: 933 women with early breast cancer and clinically negative axillary status un-
derwent breast surgery and SLN biopsy followed by axillary lymph node dissection in SLN-positive cases.
The subregional localisation of the SLN(s) was registered and statistically analysed with the clinic-
pathological characteristics of the breast tumour. In node-positive patients treated with breast-
conserving therapy in whom the SLNs were found in the anterior or posterior axillary subregions, the
axillary volumes were contoured using the Radiation Therapy Oncology Group contouring atlas (n¼ 61).
Results: In 91.1% (n¼ 797) of the cases, the SLN appeared in the anterior, posterior or central subregions.
Using HTgF, Level I or II were completely covered in 65.6% (40/61) and 6.6% (4/61) of the cases,
respectively. With STgF, the complete coverage was 0% for both levels.
6.8% (n¼ 63) of all cases had one positive lymph node in the expected ARM lymph node regions.
Discussion: A SLN is more than likely to be present in the anterior, posterior and central axillary sub-
regions. Tangential fields allow only limited coverage of the axillary volumes. Preserving the lateral
subregion during ARM may increase the possibility of understaging.
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Regional lymph node status is one of the most important
prognostic factors for disease-free and overall survival in breast
cancer [1e5]. Today, the gold-standard method for staging patients
with early-stage breast cancer with clinically negative axillary
lymph nodes is the sentinel lymph node biopsy (SLNB) [4,5].
To optimise the effectiveness of SLNB, the precise pre- and
intraoperative mapping of lymphatic drainage is mandatory [4e6].
Anatomically, the axillary region is divided into five subregions:
anterior, posterior, lateral, central and apical zones [7] (Fig. 1).
The anterior subregion is located under the lateral edge of the
pectoralis minor muscle along the lateral thoracic vein. The pos-
terior zone is found adjacent to the posterior wall of the axilla along
the thoracodorsal nerve and vessels. The lateral subregion is
located close to the lateral wall of the axilla, in relation to the
proximal part of the axillary vein. The lymph nodes in this zone
receive the vast majority of the efferent lymph vessels of the upper
limb. The central zone is in themiddle of the pyramid-shaped space
of the armpit, close to the base of the axilla. The apical subregion is
found in the apex medially to the distal part of the axillary vein.
These subregions correspond to the axillary node levels previ-
ously described by Berg [8]. The anterior, posterior and lateral
subregions constitute Level I, the central zone forms Level II and the
apical zone constitutes Level III [7].
Clear relationships between the anatomic location and meta-
static status of the SLN have been revealed [9,10]. Histologically
positive SLN was detected in Level I in 96% of cases and in Level II in
4% of cases by SPECT/CT [10].
A better understanding of the relationships between the sub-
regional drainage pattern of SLN, the subregional localisation of SLN
and the correlation to location and pathological characteristics of
the primary breast tumour could have particular importance in
determining whether ALND can be safely omitted.
The ACOSOG Z0011 trial did not perform ALND for early-stage
breast cancer patients with 1e2 metastatic SLNs (cT1-2, pN1),
and in the majority of the patients, the axilla was treated only with
tangential field irradiation following breast-conserving surgery
(BCS). After a median follow-up of 9.3 years, the data compared to
the traditional ALND group showed no differences in local
recurrence-free survival [11,12]. However, in the ACOSOG Z0011
trial, dose distribution in the axillary volumes was not reported in
the initial publication. Jagsi et al. [13] recently analysed the radio-
therapy (RT) coverage of the axillary lymph nodes of that trial. Most
patients treated in the Z0011 trial received tangential RT alone, and
some received no RT at all. Some patients received directed nodal
irradiation via a third field. They concluded that further research is
necessary to determine the optimal RT approach in patients with
low-volume axillary disease treated with SLNB alone.
A recent surgical technique that is less radical and therefore
decreases the morbidity of SLNB and ALND, especially lymphe-
dema, is ARM [14e16]. The lymphatic drainage of the upper limb
that runs through the axilla - most often the lateral subregional
lymphatic structures - is identified by injecting radioisotope or blue
dye to the ipsilateral limb subcutaneously, and these nodes arespared during the operation, removing only the lymph nodes that
drain the lymph of the breast. The technique was proven to be
feasible with a low level of evidence; however, the question of
oncological radicality still arises due to the uncertainty of the
metastatic status of the ARM lymph nodes that are not removed
[17].
We sought to determine whether there is a correlation between
the lymphatic drainage and the SLN status of the subregions. Our
main objectives were as follows:
- To examine the location of the SLN in the axillary subregions in a
representative cohort of patients with early-stage breast cancer.
- To assess statistical correlations between the clinico-
pathological characteristics of the primary breast tumour and
the subregion of the SLN.
- To analyse the subregional localisation of metastatic SLNs.
- To assess the statistical correlation between axillary subregions
outside the tangential and extended tangential RT coverage field
applied in the ACOSOG Z0011 trial and the SLN positivity within
these subregions after BCS.
- To study the axillary coverage with STgF or HTgF irradiation in
node-positive patients.
- To assess the SLN positivity rate in the lateral, unremoved sub-
region when the ARM technique is applied.Patients and methods
A retrospective cohort study was performed between March
2013 and February 2015. 933 female patients older than 18 years
were enrolled with primary unilateral invasive or microinvasive,
clinically lymph node-negative early-stage breast cancer (clinically
T 5 cm, N0M0). Exclusion criteria included previous ALND, cN1-2,
pregnancy, lactation and necessity of neoadjuvant treatment for
breast cancer [18,19].Fig. 1. Subregions of the axilla (left side, human cadaveric dissection).
B. Dorogi et al. / European Journal of Surgical Oncology 45 (2019) 103e109 105The complex oncological therapy was performed according to
the actual international guidelines [18e20] adopted by the National
Institute of Oncology and was not different from those who were
not included in the trial. Radiopharmaceutical (80 Mbq 99m Tc
labelled nanocolloid, particle size: 50e800 nm) was injected to the
intratumoural area or periareolar tissue on the day before surgery.
If the lymphoscintigraphy was unsuccessful, 2e3ml of periareolar
Patent blue 25mg/ml® dye injection was applied 10min before the
operation.
Patients then underwent a wide excision or mastectomy and
axillary SLNB followed by ALND instantly if the SLN was positive by
intraoperative imprint cytology or as a second operation if the SLN
was positive only by histological examination. If isolated tumour
cells or micrometastases were found in the SLN (n¼ 33), ALND was
omitted.
The subregional localisation of the SLN(s) was identified and
recorded on a standardised data sheet by the operating surgeons
immediately after biopsy in the operating theatre (Fig. 1). The
harvested SLNs were separated and labelled with their localisation
for pathological processing. Imprint cytology was performed
intraoperatively, and if the result was positive, the operation was
completed with ALND. Postoperatively, all the removed lymph
nodes were meticulously examined by the pathologists according
to the guidelines [21,22]. In cases of false negative SLNB, the sub-
regional localisation and the number of metastatic lymph nodes left
behind in the axilla could not be identified by our applied methods.
Following BCS, all patients had 3D-conformal RT. Patients were
placed supine with both arms up and both hands holding on to a
support during CT simulation. CT scan images with 5-mm sections
were obtained. The breast was irradiated with two opposing
tangential fields with 6MV photons. STgF margins were deter-
mined by palpation of the breast parenchymawith the addition of a
1e2-cm margin in all directions. The superior borders of these
fields intended to treat the breast only, without regard to nodal
coverage. Approximately 2 cm (max. 3 cm) of the lungwas included
in the posterior aspect of the field. In node-positive patients, an
additional field was also used to deliver an effective dose to the
axillary apex and clavicular fossa. The total dose of thewhole breast
and supraclavicular fossa was 50 Gy (25 2 Gy). Breast irradiation
was given via STgFs. The STgF upper margin was generally the base
(±1 cm) of the clavicle. Retrospectively, for the purpose of this study
in 61 randomly selected node-positive patients treated with breast-
conserving therapy inwhom the SLNs were found in the anterior orFig. 2. (a) Coverage with standard tangential field (red square). Yellow lines¼ Level I volu
coverage. Purple line¼ Level II clinical target volume; partial coverage. Blue line¼ Level III c
(red square). Yellow lines¼ Level I volumes: inner line - clinical target volume; outer line - p
partial coverage. Blue line¼ Level III clinical target volume; partial coverage.posterior axillary subregions (Level I), HTgFs were simulated using
the same CT data. HTgF consisted of a superior border placed at the
inferior edge (or below maximum 2 cm) of the humeral head.
Before RT planning, axillary volumes (Levels I, II and III) were
contoured using the RTOG (Radiation Therapy Oncology Group)
contouring atlas [23]. Coverage of the axillary volumes by tangen-
tial fields was classified according to the tangential field-planning
target volumes (Levels I, II and III) overlap: 100% overlap (com-
plete coverage), <100% overlap (partial coverage), and 0% overlap
(lack of coverage: out of field). Examples of coverages are given in
Fig. 2.
The study was approved by the institutional ethical committee
board and was registered on Clinicaltrials.gov (identifier:
NCT01804309).
The clinical trial did not alter the lege artis oncological treat-
ment and SLN intervention in any way.
All the collected data were registered in the institutional data-
base and statistically analysed using Fisher's exact test. P-values
less than 0.05 were considered statistically significant. Statistical
analysis was performed using Statistica 12.0 software (StatSoft,
Tulsa, OK) or PAST version 1.86b [24].
Results
A total of 933 women were enrolled in the study. The mean age
of the patients was 64.1 years (range 19e91 years, median: 64
years). Threewomenwere excluded because the breast tumour was
larger than 5 cm according to the postoperative pathologic exam-
ination. Another two patients were ruled out due to newly
discovered lympho-proliferative disorders affecting the axillary
lymph nodes. Another 58 patients were discarded because of an
uninterpretable sentinel data sheet or incomplete clinical-
histological data.
The detailed pathologic characteristics of the primary breast
tumours are summarised in Table 1.
Regarding the location of the breast cancer, 44.7% (n¼ 417) were
in the upper-outer, 14.7% (n¼ 137) in the upper-inner, 9.9% (n¼ 93)
in the lower-outer, 6.7% (n¼ 63) in the lower-inner quadrant, and
2.8% (n¼ 27) in the axillary process (tail of Spence); 12.8% (n¼ 119)
were central tumours and 3.5% (n¼ 33) were multiplex.
There was a significant correlation between the location and the
molecular subtype of the tumour (p¼ 0.022). Non-luminal tumours
were mainly localised in the upper quadrants (84.6% n¼ 11).mes: inner line - clinical target volume; outer line - planning target volume; partial
linical target volume; no coverage, out of field. (b) Coverage with high tangential field
lanning target volume; complete coverage. Purple line¼ Level II clinical target volume;
Table 2
Correlation between molecular subtype (column) and the location (row) of the









n % n % n % n % n %
Upper-outer 210 49.3 73 44.0 18 43.9 7 53.9 40 57.1
Upper-inner 65 15.3 39 23.5 5 12.2 4 30.8 9 12.9
Lower-outer 47 11.0 20 12.1 4 9.8 0 0 9 12.9
Lower-inner 36 8.5 13 7.8 7 17.1 0 0 1 1.4
Central 62 14.6 17 10.2 7 17.1 2 15.4 6 8.6
Axillary process 6 1.4 4 2.4 0 0 0 0 5 7.1
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the upper-outer quadrant (57.1%; n¼ 40). However, cancers in the
lower-inner quadrant were mostly Her2-enriched (17.1%; n¼ 7).
[Table 2.].
The tracer for lympho-scintigraphy was injected intratumorally
and periareolarly in 38.8% (n¼ 362) and 57.6% (n¼ 537) of the
cases, respectively. We used only radiopharmaceutical (80 Mbq 99m
Tc labelled nanocolloid) in 86.9% (n¼ 811), Patent blue dye in 4.4%
(n¼ 41) and both in 4.8% (n¼ 45) of the cases.
None of the examined characteristics of the primary breast
cancer (molecular subtype p¼ 0.360) had significant correlation
with the subregional localisation of the SLN.
We divided our study population into two groups based on the
injection site and analysed the relationships between the locationTable 1






















Luminal A 438 59.4
Luminal B 171 23.2
Luminal B-Her2þ 41 5.6
Non-luminal 73 9.9
Triple negative 14 1.9
Lymphovascular invasion
Present 322 39.3
Not present 497 60.7
Histological type
Invasive ductal carcinoma 643 73.1
Invasive lobular carcinoma 99 11.3
Other invasive 34 3.9
DCIS 75 8.5
LCIS 16 1.8
Other in situ 13 1.5
Palpability
Palpable 499 55.9





Type of breast surgery
Mastectomy 371 39.8
Breast conserving surgery 562 60.2
SLN positivity
SLN-negative patients 744 79.7
SLN-positive patients 189 20.3
Total removed SLNs 1538 na
SLNs removed per operation 1.6 na
ALND
Total number of ALND 156 16.7
Total number of removed lymph nodes 2109 na
Lymph nodes removed per ALND 13.5 na
Positive lymph nodes per ALND 406 19.3of the SLN and location of the primary breast tumour. In case of
intratumoural application, we found significant correlation be-
tween the location of the breast cancer and the subregional loca-
tion of the SLN (p¼ 0.016). However, examining only the
histologically positive SLNs, the relationship between their location
and the primary tumour location was not statistically significant
(p¼ 0.674).
If periareolar injections were used, the location of the SLN was
not dependent on the location of the primary breast tumour
(p¼ 0.398), whilst the correlation between the location of the
positive SLN and the location of the breast cancer was statistically
significant (p¼ 0.039). [Table 3.].
According to our data, tumours in the upper-outer quadrant are
least frequently drained to the anterior subregion (34.2%). Posterior
subregion receives lymph mainly from the upper-outer quadrant
(31.6%) and the axillary process (36.3%), whereas the inner and
central quadrants have very similar drainage patterns with a ten-
dency to give efferent lymphatics more often to the anterior (53.9%,
69.6% and 54.5%) and central (28.8%, 26.1% and 22.7%) lymph nodes.
The central lymph nodes receive lymphatic drainage equally from
the different quadrants of the breast [Table 3.].
An average of 1.6 (range: 1e8, median: 1) SLNs were harvested
per operation, and the SLN positivity rate was 20.3% (n¼ 189).
We also analysed the distribution pattern and metastatic status
of the SLN in the subregions of the axilla [Table 3.]. The most
common site of the SLN was the anterior subregion (39.9%;
n¼ 349), while the least common was the apical subregion (3.4%;
n¼ 30). In contrast, the positivity rate was higher in the apical
subregion (30.0%; n¼ 9) than in the anterior subregion (20.9%;
n¼ 73). The SLN was present in the lateral subregion in 5.5%
(n¼ 48) of the cases. Of these 48 lymph nodes, 11 SLNs - 1.3% of the
total cases - were positive. In the central and posterior subregions,
53 (6.1%) and 43 (4.9%) SLNs, respectively, were found to be positive
out of the 245 (28.0%) and 203 (23.2%) removed lymph nodes,
respectively.
In 91.1% (n¼ 797) of the cases, the SLN appeared in the anterior,
posterior or central subregions, corresponding to Level I and II
zones [Table 3].
In 503 patients, the SLN was located within the anterior or
posterior subregion (Level I). 111 of them (22.1%) had axillary lymph
node metastasis, and 83 (16.5%) of them were treated with RT in
our Institute. Sixty-one women were subjected to WBI. The
coverage of axillary volumes by tangential fields is given in Table 4.
There was a significant difference between the two plans regarding
the coverage of the Level I axillary volume. HTgF increased the rate
of complete coverage from 0% to 65.6% (40 of 61; p< 0.0001).
Concerning the Level II volume, the rate of complete coverage with
STgF or HTgF was 0% and 6.6% (4 of 61), respectively (p¼ 0.1198).
The rate of “out of field” cases was very high with STgF, 72.1% (44 of
61), but “out of field” cases were not observedwith HTgF irradiation
(p< 0.0001). The coverage of the Level III volume was very poor
Table 3
Correlation between the location of the primary breast tumour (column) and the subregional location of the SLN (row) if intratumoural injections were used (p¼ 0.016) and
distribution pattern and metastatic status of the SLN in the subregions of the axilla.
Upper outer Lower outer Upper inner Lower inner Central Axillary process Stained & removed SLN Positive SLN Positivity rate
anterior 65 (34.2%) 13 (41.9%) 28 (53.9%) 16 (69.6%) 12 (54.5%) 5 (45.5%) 349 (39.9%) 73 20.9%
central 55 (28.9%) 8 (25.8%) 15 (28.8%) 6 (26.1%) 5 (22.7%) 1 (9.1%) 245 (28.0%) 53 21.6%
posterior 60 (31.6%) 7 (22.6%) 6 (11.5%) 1 (4.3%) 2 (9.1%) 4 (36.3%) 203 (23.2%) 43 21.2%
lateral 6 (3.2%) 3 (9.7%) 3 (5.8%) 0 (0.0%) 1 (4.6%) 1 (9.1%) 48 (5.5%) 11 22.9%
apical 4 (2.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (9.1%) 0 (0.0%) 30 (3.4%) 9 30.0%
Table 4
Coverage of axillary volumes by tangential fields (n¼ 61).
% (No.) STgF HTgF p-value
Level I Complete 0 (0) 65.6 (40) <0.0001
Partial 100.0 (61) 34.4 (21) e
Out of field 0 (0) 0 (0) e
Level II Complete 0 (0) 6.6 (4) 0.1198
Partial 27.9 (17) 93.4 (57) e
Out of field 72.1 (44) 0 (0) <0.0001
Level III Complete 0 (0) 0 (0) e
Partial 8.2 (5) 90.2 (55) e
Out of field 91.8 (56) 9.8 (6) <0.0001
STgF, standard tangential field; HTgF, high tangential field.
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Discussion
The main objective of the study was to examine the presumable
relationship between the quadrants of the breast and the sub-
regions of the axilla and thus to describe a functional and
morphologic lymphatic drainage pattern. Furthermore, the
coverage of axillary volumes with tangential fields forWBI was also
studied.
In summary, we did not find a significant correlation between
the histopathological parameters of the primary breast cancer and
the subregional location of the SLN. However, it is obvious from the
data that the SLN is more than likely to be present in the anterior,
posterior and central axillary subregions. Moreover, the SLN posi-
tivity rate in the lateral subregion (22.9%; n¼ 11) was not negli-
gible. It is also clear from the data that upper-outer quadrant
tumours spread least frequently to the anterior lymph nodes, while
inner and central quadrant tumours have similar drainage patterns
mainly to the anterior and central subregions.
There are several studies concerning the coverage of axillary
lymph nodes from whole breast tangential field irradiation. Reed
et al. [25] reported that using STgFs, no patient received complete
coverage of the axillary Level IeII lymph node volume. They
concluded that definitive irradiation of the Level I and II axillary
lymph node regions required significant modification of the STgFs.
Krasin et al. [26] showed that the use of STgFs does not therapeu-
tically treat the regional lymph nodes. In their series, only 1 out of
25 patients had adequate coverage of the Level I region, and no
patient had adequate coverage of Level II. Reznik et al. [27]
observed that adequate coverage of Level I, defined when 95% of
the volume received 95% of the dose, was achieved in none of the
patients with normal tangents and in 6 patients (6 of 35) with high
tangents. In a study by Orecchia et al. [28], the Level I nodes were
only partially in the STgF, and the mean dose was only 48.7% of the
prescribed dose. Our study was performed to address the issue of
axillary volume coverage according to tangential field size. We
showed that no patient had complete coverage of the Level I or
Level II region with STgFs, and in 72.1% of the patients, the Level II
volume was completely out of field. Using HTgF, 65.6% of thepatients had complete coverage of Level I regions and the complete
coverage rate was only 6.6% for Level II volume. The coverage of
Level III region was very poor either with STgF (rate of out of field:
91.8%) or HTgF (rate of out of field: 9.8%).
Our results are consistent with the earlier studies that showed
that STgF does not adequately cover the axillary volumes. With
modern techniques, adequate coverage of the axillary volumes
depends on the cranial field edge. Ohashi et al. [29] used 3D-CRT
with a field-in-field technique, and half of the humeral head was
inside the field. With this technique, even the dose to the Level III
region was appropriate (V90 was 82.8%). In a study by Nagar et al.
[30], when the tangential fields were modified to include Level I
and II volumes, the mean dose (STgF vs. modified HTgF) increased
from 35Gy to 51 Gy and 11 Gy to 50 Gy, respectively. In patients
studied by Belkacemi et al. [31], the STgF was defined with the
cranial border set at 2 cm below the humeral head, while the HTgF
consisted of a superior border placed at the inferior edge of the
humeral head. Themean dose delivered to Level I with STgF or HTgF
was 20 Gy and 33Gy, respectively (p< 0.0001). We also used clas-
sical HTgF such as Belkacemi et al. [31], and the coverage of the
Level I regionwas limited (complete coverage rate 65.6%). Attempts
to increase the volume of complete coverage could induce a sig-
nificant increase in lung dose. Alco et al. [32] suggested shaping the
tangential field with multi-leaf collimators according to axillary
level volumes to ensure complete coverage, but the inclusion of the
axillary region in the target volume increased the irradiated lung
volume. Mean lung dose was with the HTgF or multi-leaf collima-
tors HTgF 6.5 and 9.6 Gy, respectively (p¼ 0.0001). To study the
adequate coverage of the axilla, Levels I, II and III should be defined
(delineated) by anatomical structures. STgFs provide limited
coverage of the axilla, but HTgFs may provide complete coverage of
Level I volume in some patients.
In our study, 9 (1.0%) positive SLNs were in the apical and 11
(1.3%) metastatic lymph nodes were in the lateral subregions. In
total, 20 patients with positive lymph nodes (2.3% of our cases)
would be left untreated if we applied tangential WBI to treat the
axilla.
In our view, for the proper treatment of the axilla, an additional
axillary and supraclavicular RT field is needed. This correlates with
the findings of the Hungarian OTOASOR prospective randomised
B. Dorogi et al. / European Journal of Surgical Oncology 45 (2019) 103e109108clinical trial with axillary and supraclavicular field irradiation in the
case of a metastatic SLN without ALND [33].
Applying the ARM technique, the lymph nodes stained with
blue dye or radioisotope are preserved to prevent postoperative
lymphedema. The subregional localisation of the ARM nodes has
not yet been clearly identified, but it seems obvious that majority of
the lymphatics draining the upper limb traverses deep in the axilla
[17]. This was also confirmed by Ikeda et al. [34], who found ARM
nodes in zones that correspond to mainly the lateral, apical and
posterior axillary subregions.
In our study, 281 (32.1%) SLNs were found within one of these
subregions, and 22.4% (n¼ 63) of them were positive. This means
that 7.2% of all our cases had one positive lymph node in the ex-
pected ARM lymph node regions.
According to these results, due to the high rate of posterior
subregional SLN drainage (21.8% n¼ 203) and SLN positivity
(21.2%), not only the ALND but also the SLNB carry a high risk of a
preserved positive lymph node and have a negative effect on the
patient's successful treatment. This corresponds to the results that
showed that the oncological safety of the ARM technique in pa-
tients with axillary lymph node metastasis from breast cancer is
questionable [35,36], and proper indications, patient selection and
further investigations are needed for the safe application of ARM
[37].
Conclusion
Our findings suggest that there is no significant correlation be-
tween the histopathological parameters of the primary breast
tumour and the subregional localisation of the SLN. The majority of
SLNs are located in the anterior and central subregions.
When primary RT is used to treat the axilla, the contouring of
the axillary lymph node levels is necessary for the proper design of
the tangential field borders. Our analysis leads to the conclusion
that STgF did not provide complete coverage of level I-II axillary
lymph nodes. The use of high tangential fields is one means of
improving axillary coverage with whole breast irradiation.
Tangential field WBI provides limited coverage of the axilla.
Only 65.6% of our patients had complete Level I coverage with high
tangential fields.
Moreover, using the ARM technique and leaving lymph nodes
behind in the apical, lateral or posterior axillary subregions may
leave behind up to 7.2% of metastatic lymph nodes, which may
elevate the risk of possible understaging or undertreatment. In
these cases, clipping the preserved lymph nodes is mandatory for
adjuvant axillary RT.
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Clinicopathological correlations of areola-sparing mastectomies 
versus nipple-sparing mastectomies: Analysis of the 
oncological and cosmetic importance of the components of the 
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In recent years, nipple-sparing mastectomy (NSM) has become the 
primary mastectomy technique.1 The oncological and cosmetic im-
portance of the nipple and separately the pigmented areola should 
be better understood by the modern breast oncoplastic surgery.
The aim of this study was to perform a long-term comparison 
of the oncological safety and cosmetic outcomes of areola-sparing 
mastectomy (ASM) with those of NSM.
This single-center retrospective comparative study was per-
formed between April 2013 and December 2018 at the National 
Institute of Oncology, Hungary, based on the prospectively led in-
stitutional database.
The diagnosis of breast cancer, staging examinations, oncological 
treatments, and follow-up was performed according to the institu-
tional protocol based on the actual ESMO guideline.
The indication for mastectomy was either therapeutic for breast 
cancer or prophylactic for patients with BRCA mutation. ASM was 
the technique first applied, while it was subsequently replaced by 
NSM after its international acceptance.
All procedures in both groups were performed with the same 
technique, applying the same type of submusculary placed tis-
sue expander with delayed-immediate implant-based breast 
reconstruction.
For the axillary staging, sentinel lymph node biopsy was per-
formed according to the criteria of the ACOSOG Z0011 trial.
Postoperative complications were assessed by applying the 
Clavien-Dindo Classification system.
For the assessment of the esthetic outcomes, a 5-point Likert 
scale was applied.
The BREAST-Q reconstruction module version 2.0 postopera-
tive questionnaire was applied at 6 months after surgery.
All the collected data were statistically analyzed using Statistica 
12.0 software (StatSoft, Tulsa, OK) or PAST version 1.86b.
After the exclusion of 24 patients, a total of 134 and 93 patients 
were enrolled in the study.
Detailed patient and tumor characteristics are summarized in 
Table 1.
The recorded early postoperative complications in the two 
groups are summarized in Table 2.
At the mean follow-up of 45 months, there was no significant 
difference in the disease-free survival (DSF) (P = .762) and overall 
survival (OS) (P = .601) between the two groups [Figure 1].
Both groups had the same objective esthetic outcomes by the 
5-point Likert scale system [Table 3].
The results of the corresponding BREAST-Q domains showed no 
significant difference between ASM and NSM patients [Table 3].
This study revealed that preservation of the nipple does not 
make oncological difference, while preserving breast projection 
and pigmented areola seems to have the same importance than the 
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TA B L E  1   (A) Patient characteristics (B) Characteristics of the primary breast tumor
(A)
ASM NSM P
Number of patients 134 93
Age (y)
Median (min.–max.) 41 (26-64) 40 (26-70) .365
BMI (kg/m2)
Mean ± SD 21.6 ± 3.1 21.2 ± 3.4 .285
Cup size n (%) n (%)
A 23 (17.2) 7 (7.5) .003
B 75 (55.9) 62 (66.7)
C 25 (18.7) 24 (25.8)
D 11 (8.2) 0 (0.0)
Indication n (%) n (%)
Therapeutic 89 (66.4) 85 (91.4) 1.2 × 10−5
Prophylactic 45 (33.6) 8 (8.6)
Operative duration (minutes)
Median (min.–max.) 80 (50-150) 76 (43-120) .431
Neoadjuvant n (%) n (%)
Chemotherapy 20 (22.5) 9 (10.6) .244
Initiation of adjuvant therapy (weeks)
Median (min.–max.) 7.4 (4.6-11.9) 8.1 (4.1-12.0) .124
Adjuvant n (%) n (%)
Chemotherapy/Biological therapy .068
Yes 34 (25.4) 19 (20.4)
No 59 (44.0) 61 (65.6)
Not reported 41 (30.6) 13 (14.0)
Radiotherapy
Yes 32 (23.9) 27 (29.0) .993
No 63 (47.0) 53 (57.0)
Not reported 39 (29.1) 13 (14.0)
Endocrine therapy
Yes 46 (34.3) 61 (65.6) .001
No 45 (33.6) 21 (22.6)




Pn = 89 (therapeutic) n = 85 (therapeutic)
pT n (%) n (%) .026
pTis 5 (5.6) 6 (7.1)
pT1 37 (41.6) 33 (38.8)
pT2 23 (25.8) 19 (22.3)
pT3 4 (4.5) 18 (21.1)
pN n (%) n (%) .900
pN0 47 (52.8) 53 (62.3)
(Continues)




Pn = 89 (therapeutic) n = 85 (therapeutic)
pN1 18 (20.2) 19 (22.3)
pN2 3 (3.4) 2 (2.4)
pN3 1 (1.1) 2 (2.4)
ypT n (%) n (%)
ypT0 5 (5.6) 4 (4.7)
ypT1 9 (10.2) 2 (2.4)
ypN2 4 (4.5) 2 (2.4)
ypN3 2 (2.2) 1 (1.2)
ypN n (%) n (%)
ypN0 11 (12.4) 6 (7.0)
ypN1 7 (7.9) 2 (2.4)
ypN2 1 (1.1) 0 (0)
ypN3 1 (1.1) 1 (1.2)
Grade (invasive breast cancer)
I 16 (18.0) 11 (12.9) .435
II 34 (38.2) 40 (47.1)
III 39 (43.8) 34 (40.0)
Receptor status
ER .004
Positive 60 (44.8) 59 (63.4)
Negative 32 (23.9) 10 (10.8)
Not reported 42 (31.3) 24 (25.8)
PR .008
Positive 56 (41.8) 56 (60.2)
Negative 35 (26.1) 13 (14.0)
Not reported 43 (32.1) 24 (25.8)
Her2 .951
Positive 20 (14.9) 15 (16.1)
Negative 71 (53.0) 52 (55.9)
Not reported 43 (32.1) 26 (28.0)
Histological type
Invasive ductal carcinoma 74 (83.2) 60 (70.6) .349
Invasive lobular carcinoma 5 (5.6) 11 (12.9)
Other invasive 4 (4.5) 6 (7.1)
DCIS 5 (5.6) 6 (7.1)
LCIS 1 (1.1) 2 (2.3)
Nipple—tumor distance (cm)
Median (min.–max.) 2.7 (0.6-7.0) 3.1 (0.7-7.0) .497
Follow-up 45 mo (range: 20.1-82.7)
Local recurrence 3 (3.4) 2 (2.4)
Distant metastatic disease 5 (5.6) 1 (1.2)
TA B L E  1   (Continued)
(Continues)
4  |     COMMENTARY
TA B L E  2   Early postoperative complications based on the Clavien-Dindo Classification
ASM NSM
P134 n (%) 93 n (%)
Grade I 12 (9.0) 9 (9.7)
infection 4 (3.0) 3 (3.2)
seroma 2 (1.5) 2 (2.1)
partial skin/ NAC necrosis 3 (2.2) 2 (2.1)
rippling 2 (1.5) 1 (1.1)
wound dehiscence 1 (0.7) 1 (1.1)
Grade II 3 (2.2) 1 (1.1)
infection 2 (1.5) 0 (0.0)
chronic seroma 1 (0.7) 1 (1.1)
Grade III 3 (2.2) 2 (2.1)
hematoma 2 (1.5) 1 (1.1)
implant loss 1 (0.7) 1 (1.1)




Pn = 89 (therapeutic) n = 85 (therapeutic)
Distant metastases-related death 2 (2.2) 1 (1.2)
Axillary surgery
Sentinel lymph node biopsy 64 (71.9) 62 (72.9) .656
Axillary lymph node dissection 23 (25.9) 19 (22.4)
No axillary surgery 2 (2.2) 0
Not reported 0 4 (4.7)
TA B L E  1   (Continued)
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F I G U R E  1   Kaplan-Meier curve 
showing (A) DSF and (B) OS of the two 
groups
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complex NAC itself. Therefore, ASM could be a suitable treatment 
option, if NSM is not oncologically feasible.
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TA B L E  3   Results of the Likert scale system (A) and the 











mean ± SD P
Satisfaction with breasts 64.9 ± 21.2 67.8 ± 17.2 .691
Psychosocial well-being 68.4 ± 18.4 72.4 ± 17.5 .123
Physical well-being 80.0 ± 14.0 76.5 ± 15.5 .232
Sexual well-being 59.1 ± 18.3 54.0 ± 20.9 .252
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A magyar emlőrákos betegek igényei  
a korszerű onkoplasztikus emlősebészeti 
ellátásra
500 beteg kérdőíves vizsgálata
Dorogi Bence dr.1, 2  ■  Mátrai Tamás dr.1  ■  Újhelyi Mihály dr.1  
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4Semmelweis Egyetem, Általános Orvostudományi Kar, II. Patológiai Intézet, Budapest
Bevezetés: A korszerű onkoplasztikus emlősebészet következményeként megjelenő jelentős emlőrekonstrukciós igény 
számos rendszerszintű kérdést vet fel. Vizsgálatra és szabályozásra várnak az onkoterápiák hatására és az idő múlásával 
bekövetkező esztétikai változások, illetve hosszú távú szövődmények miatti korrekciós műtétek indikációi; meghatá-
rozandó a helyreállító beavatkozások optimális és maximális száma, az elérni kívánt esztétikai végcél és az ezekhez 
szükséges emlősebészeti kapacitások, valamint finanszírozás.
Célkitűzés: A jelen vizsgálat célja, hogy kérdőíves vizsgálattal felmérje a magyar emlőrákos populáció korszerű emlő-
rekonstrukciós igényeit és véleményét.
Anyag és módszer: A vizsgálatba 500, mastectomián és azonnali vagy halasztott-azonnali emlőrekonstrukción átesett 
nőbeteg került bevonásra. Tizenegy kérdésből álló kérdőív segítségével történt az emlő rekonstrukciójához való is-
mereteknek és személyes viszonyulásnak, az esztétikai végeredménnyel és az ellátás szakmai színvonalával kapcsolatos 
elvárásoknak, továbbá az ellátórendszerrel és a finanszírozással kapcsolatos igényeknek a felmérése, majd elvégeztük 
az eredmények biostatisztikai elemzését.
Eredmények: A betegek medián életkora 47 év (min.–max.: 26–73) volt, döntő részük (59%; n = 294) házas volt, és 
52% (n = 260) rendelkezett egyetemi végzettséggel. A betegek 70%-a (n = 348) az emlő-helyreállítás eredményeként 
mezítelenül is nagyjából egyforma emlőket szeretett volna. Ehhez 43%-uk (n = 217) maximum kettő, 37%-uk 
(n = 184) maximum három-négy műtétet vállalna. A felmérésben részt vettek 44%-a (n = 220) szerint az egészség-
biztosítónak három-négy rekonstrukciós beavatkozást kellene támogatnia. A betegek 86%-a (n = 430) a daganatos 
emlő korszerű sebészi kezelését speciálisan képzett emlősebészre bízná. 
Következtetés: Az emlőrák modern onkoplasztikus sebészi ellátása összetett, rendszerszintű kérdéseket vet fel. Az 
emlőrákos betegek jól képzett emlősebészeket szeretnének, akik az emlőrák korszerű sebészi kezelésén túl mastecto-
mia esetén az egészségbiztosító által támogatott formában, maximum két műtéttel képesek magas esztétikai ered-
ménnyel az emlők helyreállítására.
Orv Hetil. 2020; 161(29): 1221–1228.
Kulcsszavak: onkoplasztikus emlőrekonstrukció, emlőrák, mastectomia, finanszírozás, kérdőíves vizsgálat
Assessing the needs of Hungarian breast cancer patients for modern oncoplastic 
breast surgical treatment
Questionnaire study of 500 patients 
Introduction: The significant need for breast reconstruction resulting from the spread of oncoplastic breast surgery 
raises a number of systemic issues. Clarification and regulation of the indications are needed for aesthetic changes of 
the reconstructed breast due to oncotherapy treatments, ageing and technical problems of implants; a number of 
operations, targeted aesthetic goals as well as surgical capacities and financial background should also be determined.
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Aim: Our aim was to conduct a survey on the opinions and needs of the Hungarian breast cancer population about 
a modern breast reconstruction system.
Patient and method: A study was conducted enrolling 500 patients who underwent mastectomy with immediate or 
delayed reconstruction. A structured questionnaire containing eleven questions was used to measure the attitude for 
loss and reconstruction of breast, the expectation of cosmetic outcome and qualification of the operating surgeon and 
the needs relating to the health system and funding.
Results: The median age was 47 years (min.–max.: 26–73), 59% (n = 294) was married and 52% (n = 260) had 
graduated in university. The majority of women (70%; n = 348) would like to have nakedly also similar breasts after 
the reconstruction process. To achieve this, 43% (n = 217) and 37% (n = 184) would undergo maximum two or four 
procedures, respectively, supported by the national health insurance company. 86% (n = 430) would like to choose 
qualified breast surgeon for her treatment.
Conclusion: The modern oncoplastic treatment raises complex, systemic issues. Women with breast cancer would like 
to have qualified breast surgeons restoring their breasts by two operations, all funded by the national health insurance 
company.
Keywords: oncoplastic breast reconstruction, breast cancer, mastectomy, questionnaire study, financing
Dorogi B, Mátrai T, Újhelyi M, Kenessey I, Kelemen P, Sávolt Á, Huszár O, Ping O, Pukancsik D, Mátrai Z. [Assess-
ing the needs of Hungarian breast cancer patients for modern oncoplastic breast surgical treatment. Questionnaire 
study of 500 patients]. Orv Hetil. 2020; 161(29): 1221–1228.
(Beérkezett: 2020. február 25.; elfogadva: 2020. március 19.)
Rövidítések
BRESO = (Breast Surgical Oncology) mellsebészeti onkológia 
projekt; BU = (breast unit) emlőterápiás szervezeti egység; 
CEEBCSC = (Central-Eastern European Breast Cancer Surgi-
cal Consortium) Kelet-közép-európai Emlőráksebészeti Kon-
zorcium; EBCC = (European Breast Cancer Conference) 
 Európai Emlőrák Konferencia; ECIBC = (European Commis-
sion Initiative on Breast Cancer) „Európai összefogás a mellrák 
ellen!”; EORTC = (European Organization for the Research 
and Treatment of Cancer) Európai Rákkutató és Terápiás Szer-
vezet; ESO = (European School of Oncology) Európai Onko-
lógiai Iskola; ESSO = (European Society of Surgical Oncology) 
Európai Sebészeti Onkológiai Társaság; EUBREAST = 
 European Breast Cancer Research Association of Surgical Tria-
lists; EUSOMA = European Society of Mastology; G.Re.T.A. 
= Group for Reconstructive and Therapeutic Advancements; 
NEAK = Nemzeti Egészségbiztosítási Alapkezelő; OOI = 
 Országos Onkológiai Intézet; SD = standard deviáció; UEMS = 
(European Union of Medical Specialists) Európai Szakorvosi 
Szövetség
A Nemzeti Rákregiszter adatai alapján hazánkban évente 
8300–8500 új emlőrákos megbetegedést diagnosztizál-
nak, és évente sajnálatosan mintegy 2200 nő hal bele a 
betegségbe [1]. Az emlőrák incidenciája Európában las-
san, de emelkedik. Kontinensünkön még a hasonló gaz-
dasági helyzetű országok esetében is észlelhető érdemi 
különbség az emlőrákellátási rendszerekben [2, 3]. A 
speciális igényű onkológiai ellátás egyenlőtlenségei miatt 
1998-ban Firenzében az első Európai Emlőrák Konfe-
rencián (EBCC) a multidiszciplináris emlőterápiás szer-
vezeti egységek, az ún. „breast unitok” (BU-ok) feltétel- 
és minőségbiztosítási elvárásai kerültek meghatározásra 
[4]. A European Organization for the Research and 
Treat ment of Cancer (EORTC) és a European Society of 
Mastology (EUSOMA) munkacsoportja megalkotta az 
emlőrák gyógyításával foglalkozó szakorvosokkal szem-
ben támasztott alapkövetelményeket, melyek lehetővé 
tették a szakellátás minőségbiztosítási kontrollját [5]. 
A European Union of Medical Specialists (UEMS) és a 
European Society of Surgical Oncology (ESSO) 2010-
ben emlősebészeti licencvizsgát hozott létre, amelynek 
vizsgáztatási folyamatában az Országos Onkológiai Inté-
zet (OOI) és a szerzők évek óta aktív szerepet vállalnak. 
A második Európai Emlőrák Konferencián a „Brüsszeli 
Nyilatkozatban” (The Brussels Statement) az akkreditá-
ciós feltételrendszer került létrehozásra [6]. 2019-ben az 
emlősebészeti szakismeretek intézeti, osztályos vagy 
egyéni szintű egységes európai akkreditációjára az ESSO, 
a UEMS, a European Breast Cancer Coalition (Europa 
Donna), a European School of Oncology (ESO), a Eu-
ropean Breast Cancer Research Association of Surgical 
Trialists (EUBREAST), a European Commission Initia-
tive on Breast Cancer (ECIBC), a magyar kezdeménye-
zésre létrejött Central-Eastern European Breast Cancer 
Surgical Consortium (CEEBCSC) és a Group for Re-
constructive and Therapeutic Advancements (G.Re.T.A.) 
életre hívta a Breast Surgical Oncology (BRESO-) pro-
jektet [7]. A BRESO-projekt megalkotta a teljes konti-
nensre kiterjedő, standardizált emlősebészeti curriculu-
mot és minőségbiztosítási rendszert, valamint annak 
akkreditációs feltételeit. A felsorolt nyilatkozatok hatásá-
ra az Európai Parlament 2003-ban állásfoglalást adott ki, 
amely egyértelműen támogatta a minősített BU-ok 
 intézményrendszerének európai elterjesztését, illetve 
2013-ban megjelent a komplexebb ellátásra alkalmas 
emlőközpontok (breast centres) minimálfeltételeinek 
összefoglalója [8].
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Az akkreditált BU-minősítés követelménye, hogy az 
adott centrumban a multidiszciplináris emlőterápiás bi-
zottsági döntést követően évente legalább 150, újonnan 
diagnosztizált emlőrákos beteg komplex onkológiai ke-
zelése történjen, folyamatosan frissített szakmai proto-
kollok alapján. Az akkreditáció elengedhetetlen része a 
standardizált adatbázis kialakítása és vezetése, a lakossági 
mammográfiás szűrés biztosítása, valamint oktatási és 
egyéb tudományos kutatási tevékenységek ellátása is [8–
10]. A BU-rendszer hazai helyzetéről és eredményeiről 
munkacsoportunk 2016-ban számolt be az Orvosi Heti-
lapban [11]. 
A korszerű onkoplasztikus emlősebészet elmúlt évti-
zedekben történő gyors elterjedése következtében nap-
jainkban nemcsak az emlőtumor eltávolítása, hanem a 
nőiesség szimbólumának számító emlők esztétikailag tel-
jes megőrzése vagy postmastectomiás helyreállítása is a 
sebészeti szakellátás alapvető része [12–14]. Minden 
olyan emlődaganatos nő számára, akinél sajnálatosan 
mastectomia szükséges, ellenjavallatok hiányában fel kell 
ajánlani és biztosítani kell tudni az emlő rekonstrukciójá-
nak lehetőségét [15]. A fentiek miatt megjelenő emlőre-
konstrukciós igény már önmagában nemcsak az emlő- és 
plasztikai sebészeket állítja kihívás elé, hanem rendszer-
szintű feladatokat ró minden európai országra. 
Az alap helyreállító sebészeti feladatokon túl azonban 
szakmailag tisztázásra várnak az onkoplasztikus műkö-
désből eredő további emlősebészeti feladatok és indiká-
ciók, amelyek értékelése és szabályozott ellátása még a 
jelenleg már fejlett emlősebészeti ellátórendszereknek is 
számos ismeretlen faktort tartalmaz. A primer, rendszer-
szinten tömegeken végzett emlő-helyreállítás másodla-
gos feladatköre jelentősen kibővül. Új ellátási feladatok 
jelennek meg, melyek szintén az onkológiai ellátórend-
szert terhelik, mint – a hosszan (akár 5–10 évig) tartó 
endokrin kezelések következtében ismerten fellépő test-
súlygyarapodásból [16–18] vagy a kiváló túlélési ered-
mények alapján az életkor előrehaladásával („aging”) 
[19–21], illetve az onkoterápiás beavatkozások (például 
radioterápia) következtében [22] – a rekonstruált emlőn 
vagy a szimmetrizált ellenoldali emlőn jelentkező eszté-
tikai változások és az ezekből eredő további lehetséges 
műtéti indikációk. A fenti új szakmai elvárásokon túl a 
szükséges emlősebészeti ellátórendszer humánerőforrás- 
és műtéti kapacitásainak meghatározásához számba kell 
venni az onkológiai emlőrekonstrukció során beültetett 
implantátumok hosszú távú technikai problémáiból ere-
dő szövődmények (például implantátumruptura), illetve 
állapotok (például kapszuláris kontraktúra) szakellátásá-
nak igényét is, valamint az ellenoldali emlő szimmetrizá-
ciójának megváltozásából eredő további lehetséges mű-
téti korrekciók tömeges jelentkezésének kérdéskörét is. 
Mindezen szakmai tények figyelembevételével szükséges 
meghatározni az onkoplasztikus rekonstrukciós beavat-
kozásokkal elérni kívánt, reális esztétikai végcélt, illetve 
az ehhez szükséges, az onkológiai ellátórendszer kerete-
in belül elvégezhető helyreállító műtétek optimális, illet-
ve maximális számát. Az onkoplasztikus ellátás mint 
standard emlőráksebészeti ellátás tehát a primer onkoló-
giai és helyreállító sebészeten túlmutató, sokszor szak-
mailag nehezen meghatározható szubjektív indikációkat 
vagy élethosszig tartó kozmetikai változások lehetséges 
korrekcióit is magában foglalja. 
Az új emlősebészeti igények megismerése, tudomá-
nyos alapú meghatározása és reális értékelése nélkülöz-
hetetlen alap a szükséges feltételrendszer kialakításához. 
Jelenleg hazánkban a Nemzeti Egészségbiztosítási Alap-
kezelő (NEAK) az eltávolított daganatos emlő helyreállí-
tását minden magyar biztosított számára finanszírozza, 
ugyanakkor ezen összetett új indikációkat jelenleg rend-
szerszinten nem ismeri fel, és ennek megfelelően szak-
mailag nem is kezeli. Az emlő-helyreállítás jelentős vív-
mány az emlőrákban szenvedő magyarok számára, de a 
rekonstrukciós igény emelkedése és az indikációs kör ki-
bővülése esetén e népbetegség magas esetszámánál a kö-
zeljövőben lavinaszerű, szabályozatlan helyzet alakulhat 
ki, amelynek megelőzése szakmai ismereteket és terve-
zést igényel. 
A fentiek alapján a jelen kérdőíves prospektív vizsgálat 
célja a korszerű onkoplasztikus ellátással kapcsolatban a 
betegek igényeinek és elvárásainak megismerése és tudo-
mányos igényű elemzése.
Módszer
A vizsgálatba az OOI Emlő-Lágyrész Daganatsebészeti 
Osztályán 2015. január és 2017. december között 500, 
emlőrák miatt mastectomiára szoruló nőbeteg került be-
vonásra, akiknél vagy a daganatos emlő eltávolításával 
egy időben (azonnali) vagy egy időben megkezdett (pél-
dául szövettágító expander beültetésével) és második lé-
pésben befejezett (halasztott-azonnali emlő-helyreállí-
tás) emlőrekonstrukció történt. A vizsgálatot és a 
kérdőívet az intézet Etikai Bizottsága jóváhagyta. A köz-
lemény nem sérti a helsinki, illetve a tokiói deklaráció 
követelményeit [23].
A betegek kivizsgálása és kezelése minden esetben az 
OOI által alkalmazott aktuális nemzetközi és hazai irány-
elvek szerint történt [24–26]; a műtéteket az intézeti 
Emlőrák Terápiás Bizottság döntését követően tapasztalt 
és nemzetközi szakvizsgával minősített emlősebészek és 
plasztikai sebészek végezték.
A kérdőívek az emlőműtétet megelőző napon kerültek 
kiosztásra a betegeknek, kitöltésük a beavatkozás előtt 
történt önkéntesen és anonim módon.
Az életkorra, a legmagasabb iskolai végzettségre és a 
családi állapotra irányuló kérdéseket követően a kérdőív 
további tizenegy, strukturált kérdést tartalmazott. A kér-
dések a betegeknek az emlő elvesztésével kapcsolatos ér-
zelmi és pszichés állapotára és viszonyulására, illetve az 
emlő helyreállításával kapcsolatos ismereteikre és akara-
tukra, valamint a rekonstruált emlők esztétikai végered-
ményével és az operáló orvos szakképzettségével kapcso-
latos elvárásaikra, továbbá az emlősebészeti ellátással 
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1. táblázat Az onkoplasztikus ellátás felmérését vizsgáló strukturált kérdőív és a kapott válaszok
1. Mennyire zavarja az emlő elvesztése vagy esztétikai deformitása egy 1-től 10-ig terjedő skálán? (1: nem zavar – 10: rettentően zavar)
n Átlag Medián Standard deviáció
495 8 9 3
Hiányzó adat = 5 (1%)
2. Mikor történik Önnél az emlő rekonstrukciója?
A daganat eltávolítása után hónapokkal, évekkel. A daganat eltávolításával egy időben.
167 (33%) 307 (61%)
Hiányzó adat = 26 (5%)
3. Ön reálisan mit vár az emlő helyreállításától?
Legyen „valamiféle” emlőm. Legyen melltartóban szép 
dekoltázsom.
Legyen szebb emlőm, mint a 
betegség előtt.
Legyenek tökéletes emlőim.
46 (9%) 194 (39%) 140 (28%) 99 (20%)
Hiányzó adat = 21 (4%)
4. Önnek reálisan milyen mértékű szimmetria fogadható el az emlő-helyreállítás végén?
A természetes emlőim sem voltak 
szimmetrikusak, ezért nem fontos, ha 
nem egyformák a rekonstruált emlőim.
Legyenek ruhában vagy 
melltartóban nagyjából egyfor-
mák a rekonstruált emlőim.
Legyenek mezítelenül is 
nagyjából egyformák a 
rekonstruált emlőim.
Csak a teljes szimmetria az 
elfogadható számomra.
12 (2%) 105 (21%) 348 (70%) 32 (6%)
Hiányzó adat = 3 (1%)
5. Maximum hány műtétet vállalna altatásban az emlők helyreállításához?
Maximum kettőt. Maximum 3-4-et. Maximum 5-6-ot. Akármennyit.
217 (43%) 184 (37%) 25 (5%) 67 (13%)
Hiányzó adat = 7 (1%)
6. Ön szerint hány rekonstrukciós műtét „állami” finanszírozása jogos egy általános biztosítottnak, ha ismert, hogy a lehetőségek nem végtelenek?
Maximum kettőnek. Maximum 3-4-nek. Akármennyinek.
107 (21%) 220 (44%) 157 (31%)
Hiányzó adat = 16 (3%)
7. Ön szerint a most helyreállítandó/helyreállított emlők, ha idővel például az öregedéssel megváltoznak, akkor az:
nem indokol további helyreállítást, mert 
természetes folyamat.
természetes folyamat, amely a jövőben egyéni 
esztétikai sebészeti kérdés.
évtizedek múlva is rekonstrukciós sebészetnek 
és nem esztétikai műtétnek számít.
71 (14%) 275 (55%) 139 (28%)
Hiányzó adat = 15 (3%)
8. Beleegyezne-e abba, hogy az Ön emlő-helyreállítását ne plasztikai sebész szakorvos, hanem általános sebész szakorvos végezze?
Igen. Nem.
40 (8%) 448 (90%)
Hiányzó adat = 12 (2%)
9. Ön szerint a daganatos emlők korszerű sebészeti ellátását (onkoplasztika, emlő-helyreállítás stb.) ki végezze hazánkban?
Általános sebész, mint hazánkban 
ma a legtöbbször.
Nőgyógyász, mint hazánkban ma 
néhány helyen.
Plasztikai sebész. Speciálisan felkészült emlősebész, ha 
kell, plasztikai sebészt is bevonva.
5 (1%) 3 (1%) 54 (11%) 430 (86%)
Hiányzó adat = 8 (2%)
10. Ön szerint mennyire fogadható el, hogy hazánkban a XXI. században csak egy-két kórházban van speciálisan felkészült, korszerű emlősebészet?
Így jó, ahogy van. Sajnálatos, de ez van. Nagyon sajnálatos, aki jobbat 
akar, az elmegy magánellátásba.
Elfogadhatatlan, biztosítani kell  
a korszerű, specializált emlő-
sebészetet.
2 (1%) 51 (10%) 46 (9%) 394 (79%)
Hiányzó adat = 7 (1%)
11. Ön szerint gyógyulását érdemben befolyásolja-e, hogy emlősebész specialista operálja?
Nem befolyásolja. Befolyásolja. Nagyon befolyásolja. Az egyik legfontosabb.
14 (3%) 54 (11%) 111 (22%) 316 (63%)
Hiányzó adat = 5 (1%)
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szemben rendszerszinten támasztott igényekre és azok 
feltételrendszerére (például finanszírozás) vonatkoztak 
(1. táblázat).
A kapott válaszok adatai, valamint azok szociális össze-
függései Fisher-egzakt teszt és khi-négyzet-próba alkal-
mazásával kerültek biostatisztikai elemzésre. A 0,05 alat-
ti p-érték számított szignifikánsnak. 
A statisztikai analízis Statistica 12.0 (StatSoft, Tulsa, 
OK, Amerikai Egyesült Államok) és PAST version 1.86b 
szoftverek segítségével történt [27].
Eredmények
A nőbetegek medián életkora 47 év (min.–max.: 26–73) 
volt. A felmérésben részt vettek 52%-a (n = 260) rendel-
kezett felsőfokú végzettséggel, és nagyobb részük (59%; 
n = 294) házasságban élt. A vizsgált populáció adatait a 
2. táblázat foglalja össze.
Érthetően az emlő elvesztése jelentősen zavarta a 
megkérdezetteket, az 1-től 10-ig terjedő skálán átlag 8 ± 
3 (átlag ± standard deviáció [SD]) értéket adtak az erre a 
kérdésre vonatkozó válaszok; illetve a válaszok között 
sem az iskolai végzettség, sem a családi állapot tekinteté-
ben nem volt különbség (1. ábra). 
Az esetek közel kétharmadában (61%; n = 307) tör-
tént azonnali rekonstrukció, míg 167 beteg (33%) esetén 
az emlő-helyreállítás halasztott-azonnali módon történt, 
és a válaszadás a daganat eltávolítását követően hónapok-
kal vagy évekkel később, a rekonstrukció befejező lépése-
kor történt meg. 
A válaszok alapján a megkérdezett nők 39%-a (n = 
194) megelégedne a melltartóban szép dekoltázst ered-
ményező emlőkkel, azonban 28%-uk (n = 140) az erede-
tinél szebb, 20%-uk (n = 99) pedig egyenesen tökéletes 
emlőket szeretne a rekonstrukciós folyamat végén. Az 
elvárások tekintetében szignifikáns összefüggés mutat-
kozott az iskolai végzettséggel: a magasabb iskolai vég-
zettség magasabb elvárásokkal társult (p<0,05). A szim-
metria tekintetében határozott véleményt képviseltek a betegek, nem volt különbség sem a családi állapot, sem 
az iskolázottság tekintetében: a nők 70%-a (n = 348) kí-
vánna a rekonstrukciós folyamat végén mezítelenül is 
nagyjából egyforma emlőket. 
Az emlők optimális esztétikai végeredményéhez a fel-
mérésben részt vevők 43%-a (n = 217) maximum kettő, 
37%-a (n = 184) akár három vagy négy műtétet is vál-
lalna. 
A beavatkozások finanszírozásának kérdésében meg-
oszlottak a vélemények: 44% (n = 220) szerint maximum 
három-négy, 21% (n = 107) szerint legfeljebb csak két 
műtétet kellene térítenie az egészségbiztosítónak, míg a 
betegek közel harmada (31%; n = 157) van azon az állás-
ponton, hogy akármennyi beavatkozásra van is szükség, 
mindegyiket fizetnie kellene az állami biztosítónak. A 
középiskolai végzettségűek kevésbé tartják jogosnak álla-
mi finanszírozásból a több műtétet, az egyetemi végzett-
ségűek inkább (p<0,05).
































































































































































1. ábra Az emlő elvesztésének értékelése iskolai végzettség és családi 
állapot szerint (boxplot)
2. táblázat A vizsgálatban részt vett betegek általános tulajdonságai
Életkor
n Átlag Medián Minimum Maximum
485 48 47 26 73
Hiányzó adat = 15 (3%)
A legmagasabb iskolai végzettség 
8 általános Középiskola Egyetem
7 (1%) 218 (44%) 260 (52%)
Hiányzó adat = 15 (3%)
Családi állapot
Hajadon Házas Elvált Özvegy
52 (10%) 294 (59%) 119 (24%) 20 (4%)
Hiányzó adat = 15 (3%)
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A betegek 55%-a (n = 275) gondolja úgy, hogy a hely-
reállított emlőknek az életkor miatt bekövetkező válto-
zása egyéni esztétikai, plasztikai sebészeti kérdést jelent, 
azonban 28% (n = 139) szerint ez akár évtizedek múlva 
is a rekonstrukciós műtétsorozat, tehát az onkológiai 
helyreállító sebészet és nem az esztétikai sebészet megol-
dandó feladatát képezi. 
Egyértelmű állaspontot képviselnek a betegek a be-
avatkozást végző orvossal kapcsolatban: 90%-uk (n = 
448) plasztikai sebészre bízná a rekonstrukciót, továbbá 
86%-uk (n = 430) szerint a daganatos emlők korszerű 
ellátását speciálisan felkészült emlősebészeknek kellene 
végezniük a jelenlegi általános sebészeti ellátással szem-
ben. 
A válaszadók döntő többsége (79%; n = 394) nem 
tartja elfogadhatónak, hogy jelenleg Magyarországon 
csak egy-két, speciálisan felkészült emlősebészeti köz-
pont működik, míg 10% (n = 51) beletörődik a jelenlegi 
helyzetbe, és további 9% (n = 46) úgy vélekedik, hogy a 
jobb ellátás érdekében a magánellátás felé szükséges for-
dulni. 
A betegek 96%-a (n = 481) szerint a gyógyulást ér-
demben befolyásolja, hogy emlősebész végzi-e a műté-
tet, 63% (n = 316) pedig egyenesen úgy gondolja, hogy 
ez az egyik legfontosabb tényező egészsége visszanyeré-
se érdekében. 
Megbeszélés
A modern onkoplasztikus szemlélet elterjedése paradig-
maváltást eredményezett az emlőrák ellátásában [28–
30]. A sebészi kezelés az emlődaganat eltávolítását jelen-
tő műtéttől az emlők teljes helyreállítását is magában 
foglaló komplex, akár kétoldali műtétek vagy műtéti so-
rozatok felé mozdult el. Ez számos rendszerszintű fel-
adatot vet fel, például azt, hogy az onkológiai kontrol-
lokkal párhuzamosan folytatandó a rekonstruált emlők 
élethosszig tartó plasztikai sebészeti utánkövetése és 
szükséges kozmetikai korrekciói. A fenti igények, indiká-
ciók az emlő onkológiai ellátásában újszerűek, melyek 
pontos meghatározása, az ellátás feladatkörének és tár-
gyi, valamint humánerőforrás-kívánalmainak tisztázása a 
korszerű, betegközpontú ellátórendszer kialakítása és 
magas szintű, hosszú távú üzemeltetése céljából elen-
gedhetetlen. Mindezek alapját képezi a betegek igényei-
nek és elvárásainak megismerése és elemzése.
A jelen tanulmány az emlő elvesztésén és rekonstruk-
ciós folyamaton átesett nőbetegeknek a rendszerrel kap-
csolatos igényeit és elvárásait mérte fel. Az eredmények-
ből látható, hogy az emlő elvesztése iskolai végzettségtől 
és családi állapottól függetlenül jelentősen zavarja a nő-
betegeket (1. ábra). Ezek az adatok megfelelnek azok-
nak az eredményeknek, amelyeket munkacsoportunk 
2014-ben közölt, 500 nőbeteg 2010 és 2011 közötti 
kérdőíves vizsgálata alapján [28]. A felmérés szerint a be-
tegek 30%-a (n = 148) közepesen, 40%-a (n = 198) na-
gyon félt az emlő elvesztésétől, közel 50%-uk (46%; n = 
224) szeretett volna rekonstrukciót, de erről szinte sem-
mit (32%; n = 158) vagy nagyon keveset (56%; n = 279) 
tudtak [28]. Az intézetben folyó onkoplasztikus emlőse-
bészeti tevékenység alapján, a 2017–2018-ban elvégzett 
ugyanazon kérdőíves felmérés megismétlése szerint a 
nők továbbra is ugyanúgy félnek az emlő elvesztésétől, 
de a korábbi adatokkal (10%; n = 48) szemben a megkér-
dezetteknek már a 30%-a (n = 152) ismerte az emlőre-
konstrukciós lehetőségeket, mely információkat főleg a 
sebésztől (52%; n = 258) vagy az internetről (27%; n = 
135) gyűjtötték be. Ezek alapján kimondható, hogy az 
emlő elvesztése jelentős mértékben terheli pszichésen az 
emlőrákos betegeket szociális helyzettől és iskolai vég-
zettségtől függetlenül, tehát az onkoplasztikus ellátó-
rendszer kiterjesztése hazánkban indokolt és szükséges. 
Az elmúlt 6–8 évben az onkoplasztikus szemlélet a ma-
gyar nők között elterjedt és ismertté vált, amivel párhu-
zamosan nő a lakosság igénye is erre a speciális egészség-
ügyi szolgáltatásra, melyet az ellátórendszernek ki kell 
tudnia elégítenie.
A páciensek a műtétek esztétikai eredményét tekintve 
magas elvárással rendelkeznek, összesen a nők közel fele 
(48%; n = 239) szeretne az eredetinél is szebb (28%; n = 
140) vagy tökéletes (20%; n = 99) emlőket a rekonstruk-
ciós folyamat végén. A reális elvárásokkal kapcsolatban 
történő preoperatív betegfelvilágosítás kiemelt fontossá-
gú, ugyanis az onkoplasztikus beavatkozások nem eszté-
tikai műtétek, és bár technikájukból eredően gyakran az 
esztétikai műtétekkel megegyező, magas szintű eredmé-
nyekre képesek, teljesen alárendeltek az onkológiai be-
avatkozásoknak (például a reszekció helye, mértéke, ra-
dioterápia stb.), így eredményességüket a plasztikai 
sebészeti beavatkozáson túl számos egyéb tényező is be-
folyásolja [31].
A felmérésben részt vett nőbetegek döntő része (70%; 
n = 348) családi állapottól és végzettségtől függetlenül 
kívánna a rekonstrukciós folyamat végén mezítelenül is 
nagyjából egyforma emlőket. Tekintettel arra, hogy a 
legtöbbször implantátumalapú postmastectomiás re-
konstrukciók során a két emlő szerkezete különbözik, 
idővel az emlők aszimmetriája fokozódni fog, mivel a 
felvarrt saját egészséges emlő máshogy fog viselkedni bi-
ológiai tulajdonságai miatt, mint a csak implantátumból 
és bőrből álló emlő. Ez alapján a szimmetria időbeli vál-
tozása miatti másodlagos műtéti igények jelennek meg a 
betegek részéről. 
A kívánt magas kozmetikai eredményt a nők leginkább 
kettő, de maximum három-négy műtét segítségével sze-
retnék elérni, melyeket véleményük szerint az egészség-
biztosítónak kellene térítenie. Egyészt a jövőben kerülni 
szükséges az onkológiai finanszírozású esztétikai műté-
teket, aminek kérdésfelvetése is nehezen megoldandó 
etikai és szakmai problémát jelent, másrészt a műtéti so-
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rozatból álló kezelés óriási megterhelést jelent az ellátó-
rendszer számára, mintha több száz vagy ezer esettel 
nőne az emlőrák miatt operáltak éves száma. Jelenleg a 
rendszer ezt elemeiben képes, de összességében kérdé-
ses-e, hogy képes lenne biztosítani, így ebben az irány-
ban a betegek, a szakma és a szakmapolitika együttes 
munkájára van szükség.
A betegek sebészi kezelésüket specializált centrumok-
ban, speciálisan képzett emlősebészekre bíznák, mert vé-
leményük szerint gyógyulásukat ez érdemben befolyá-
solja. Az emlőrák kezelésében az emlősebész is önálló 
prognosztikai faktor [32], de a BU-ok hazai elterjeszté-
se, minőségbiztosítása, valamint a BRESO-akkreditáció-
val a betegek túlélése és életminősége is tovább javítható 
a XXI. században [7]. 
A hazánkban tapasztalt mastectomiát követő onko-
plasztikus emlő-helyreállítás iránti igény megfelel a nem-
zetközi trendeknek: brit tanulmány szerint az emlőeltá-
volításra váró nőbetegek 50%-a [33], míg az Ananian és 
mtsai által végzett francia tanulmány szerint a megkérde-
zettek 81%-a szeretne rekonstrukciót [34]. A nemzetkö-
zi helyzethez hasonlóan vizsgálatunk alapján a magyar 
betegek fő információs forrása szintén a sebész, illetve az 
internet [35, 36]. Az érintett nők igényeinek megisme-
rése, a megfelelő tájékoztatás, a hozzáférhetőség növelé-
se, a betegutak megszervezése és az egészségügyi rend-
szer megfelelő strukturálása nélkülözhetetlen az 
onkoplasztikus emlőrákellátás magas szintű kiterjesztésé-
hez [37, 38].
Következtetések
A korszerű onkoplasztikus ellátás új, összetett, rendszer-
szintű onkológiai és helyreállító sebészeti szakmai kérdé-
seket vet fel, amelyek a betegek informáltságával, a 
 humánerőforrás szakképzésével, az ellátórendszer kapa-
citásaival és a finanszírozásával kapcsolatos új feladatokat 
eredményeznek. Az emlőrákban szenvedő betegek jól 
képzett emlősebészek által szakmai központokban vég-
zett korszerű műtéteket szeretnének, amelyektől testi és 
lelki gyógyulásukat bizalommal remélhetik. 
Anyagi támogatás: A közlemény megírása, illetve a kuta-
tómunka anyagi támogatásban nem részesült. A klinikai 
feldolgozás a 2019-es Témakiválósági Program 
(TUDFO/51757/2019-ITM) támogatásában része-
sült.
Szerzői munkamegosztás: A szerzők egyenlő mértékben 
vettek részt a kutatómunkában és a kézirat elkészítésé-
ben. A cikk végleges változatát valamennyi szerző elol-
vasta és jóváhagyta.
Érdekeltségek: A szerzőknek nincsenek érdekeltségeik.
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